



Whole Gene Health

Your Complete Genetic Blueprint

Personalized Genetic Health Report

Watson D. Crick

June 25, 2026

wholegene.health • Your Complete Genetic Blueprint

Confidential Report – For Patient Use Only



Whole Gene Health

Table of Contents

Navigate your personalized genetic health report

1	Executive Summary	Section 1
2	Understanding Methylation	Section 2
3	MTHFR & Core Methylation Variants	Section 3
4	B12 Recycling, Transsulfuration & Byproduct Processing	Section 4
5	Detoxification Analysis	Section 5
6	Phase 1 Detoxification Genes	Section 6
7	Phase 2 Detoxification Genes	Section 7
8	Cardiovascular Health	Section 8

9	Mood & Neurotransmitter Analysis	Section 9
10	Dopamine Metabolism	Section 10
11	Serotonin & GABA Systems	Section 11
12	Sleep & Circadian Rhythm	Section 12
13	Vitamin & Nutrient Metabolism	Section 13
14	Complete Supplement Protocol	Section 14
15	Implementation Schedule	Section 15
16	Drug Interactions & Safety	Section 16
17	Resources & Brand Recommendations	Section 17
18	Peptide Analysis	Section 18
19	What We Found in Your Genetic Data	Section 19

20	GLP-1 Agonist Response	Section 20
21	GH Axis Peptides	Section 21
22	Tissue Repair Peptides	Section 22
23	Cognitive Peptides	Section 23
24	Peptide Recommendation Summary	Section 24

This report contains personalized information based on your genetic profile. Please consult with a qualified healthcare provider before starting any supplement regimen.

Executive Summary

Your Genetic Blueprint at a Glance

Welcome, Watson. This report from Whole Gene Health offers an educational exploration of your genetic profile, with particular attention to the questions you raised about caffeine sensitivity, afternoon brain fog, slow sleep onset, and occasional heart palpitations after coffee. Your genetic data reveals several notable patterns that research has linked to these very experiences. This is educational information only, not medical advice, and individual responses vary significantly from research findings. Please consult your healthcare provider before making changes to supplements, diet, or lifestyle.

Your results highlight a particularly interesting combination relevant to your stated concerns. You carry two copies of the slower variant in **CYP1A2** (the gene encoding the primary enzyme that breaks down caffeine), which research associates with slower caffeine metabolism. You also carry the higher-activity form of **COMT** (an enzyme that clears stress chemicals like adrenaline and dopamine) alongside two copies of the reduced-function variant in **MTHFR C677T** (a key enzyme in folate processing). Together, this pattern offers a plausible, research-informed lens through which to view your afternoon fog, your difficulty falling asleep, and your post-coffee palpitations.

Top Priority Findings

Gene	Variant	Status	Relevance to Your Concerns
CYP1A2	163A>C (rs762551)	-/- (AA, slow form)	Slower caffeine clearance — may explain caffeine sensitivity and palpitations
MTHFR	C677T (rs1801133)	+/+	Reduced folate processing — relevant to energy, mood, homocysteine
COMT	V158M (rs4680)	-/- (GG, high activity)	Faster breakdown of dopamine; interacts with stimulants and stress
VDR	Taq (rs731236)	+/+	Vitamin D receptor variation — relevant to your winter-only vitamin D use
BHMT-08	rs651852	+/+	Alternate methylation pathway variation

Gene	Variant	Status	Relevance to Your Concerns
AHCY	rs819147/819134/819171	+/+	Methylation cycle byproduct processing

Overview of a Research-Informed Strategy

Based on what research has observed in individuals with similar profiles, several educational considerations emerge. Because your MTHFR C677T status (two copies of the reduced-function variant) is associated with reduced folate metabolism, studies indicate that the methylated form of folate (L-5-MTHF) may be processed more readily than synthetic folic acid. Your CYP1A2 slow-metabolizer status suggests that timing and quantity of caffeine may be worth discussing with your healthcare provider, as research connects this variant to differences in caffeine pharmacokinetics^[1].

- **Methylation support:** Research suggests individuals with MTHFR variants may benefit from methylated B-vitamin forms (methylfolate, methylcobalamin) rather than synthetic folic acid.
- **Caffeine awareness:** Your slow CYP1A2 profile may warrant discussing caffeine timing (e.g., avoiding late-day intake) with your provider, given your palpitation and sleep concerns.
- **Vitamin D consistency:** Your VDR variants combined with winter-only supplementation may be worth revisiting with your provider for year-round considerations.
- **Sleep onset:** The interaction of caffeine sensitivity and stress-chemical clearance may relate to your difficulty falling asleep.

Important Context for Your Heart Palpitations

You mentioned occasional heart palpitations after coffee. While your slow CYP1A2 caffeine-metabolizing profile offers a possible genetic context, palpitations always warrant evaluation by a qualified healthcare provider to rule out other causes. Genetics is only one piece of the picture. This report does not diagnose any condition. Please discuss any cardiac symptoms directly with your physician.

How to Read This Report

Throughout this report, genetic results are shown as **-/-** (no copies of the variant tested), **+/-** (one copy), or **+/+** (two copies). Note that for some genes, the company that generated your raw data reports the wild-type (common) form as the "variant" — context is provided where this matters. Individual responses vary significantly, and this is educational information only, not medical advice.

References

1. The Effect of CYP1A2 Gene Polymorphisms on Caffeine Pharmacokinetics and Exercise Performance in Male Recreational Athletes. European journal of sport science. PMID: 42230302



Understanding Methylation

What Is Methylation and Why It Matters

Methylation is one of the body's most fundamental biochemical processes — a chemical relay in which small tags called methyl groups (a carbon atom bonded to three hydrogen atoms) are passed from molecule to molecule. This seemingly simple transfer supports an enormous range of functions, including building and repairing DNA, producing and breaking down brain chemicals (neurotransmitters), processing hormones, supporting detoxification, and recycling homocysteine (an amino acid that, at elevated levels, has been studied in relation to cardiovascular and cognitive health).

At the heart of methylation is a molecule called **SAMe (S-adenosylmethionine, the body's primary methyl donor molecule)**. When SAMe donates its methyl group to another molecule, it becomes **SAH (S-adenosylhomocysteine, a byproduct formed when SAMe donates a methyl group)**. SAH must then be cleared efficiently, because when SAH accumulates, it can slow down methylation reactions throughout the body. The enzymes encoded by the genes in your methylation panel — MTHFR, MTR, MTRR, BHMT, AHCY, CBS, and others — all work together to keep this cycle running smoothly and to regenerate the raw materials needed for the next round of methyl transfers.

The Methylation Cycle in Plain Language

Think of methylation as a postal system delivering tiny chemical packages (methyl groups). Folate and vitamin B12 act as delivery trucks, MTHFR prepares the packages for shipping, and enzymes like AHCY and CBS handle the recycling and waste processing. When one part of the system runs slower due to genetic variation, the body can often compensate — but providing the right nutritional raw materials may help support smoother operation. Always consult your healthcare provider before starting any supplement.

Your Methylation Gene Landscape

Your methylation profile shows a mix of common and notable variants. The most significant finding is your **MTHFR C677T (+/+)** status, which research associates with substantially reduced enzyme activity. You also carry several heterozygous (one-copy) variants in the MTRR and CBS genes, and homozygous variants in BHMT-O8 and the

AHCY genes. Importantly, your **MTHFR A1298C** is normal (-/-), and your **MTR A2756G** and **MTRR A66G** are also normal — these are favorable findings that may partially offset the impact of your C677T status.

Gene	Variant	Your Status	General Role
MTHFR	C677T	+/+	Converts folate into its active methylation form
MTHFR	A1298C	-/-	Supports BH4 production (favorable result)
MTR	A2756G	-/-	Uses B12 to recycle homocysteine (favorable)
MTRR	A66G	-/-	Recycles B12 (favorable result)
MTRR	H595Y / K350A / A664A	+/-	Supports B12 recycling (one copy each)
CBS	A360A	+/-	Transsulfuration pathway entry point
BHMT	O8	+/+	Alternate route to recycle homocysteine
AHCY	O1 / O2 / 19	+/+	Processes the SAH byproduct
SHMT1	C1420T	+/-	Directs folate toward DNA synthesis vs. methylation

Studies indicate that variations across these genes can influence how efficiently the body manages folate, B12, and homocysteine^[1]. Research has also linked the MTHFR C677T variant to differences in folate status and homocysteine levels, particularly when dietary folate intake is suboptimal. Given that you travel frequently for work and often skip breakfast, your dietary folate intake may be inconsistent — a factor worth discussing with your healthcare provider in the context of your genetics.

A Note on Interpretation

Carrying a methylation variant does not mean a gene is "broken." It means the corresponding enzyme may work at an altered efficiency. Many people with these variants live in excellent health. The goal of this educational report is to help you and your healthcare provider consider whether nutritional or lifestyle adjustments might support your individual biochemistry. Results are not guaranteed and may differ by individual.

References

1. Association between maternal MTHFR and MTRR gene polymorphisms and the risk of congenital heart disease in newborns. BMC pediatrics. PMID: [41896807](#)



MTHFR & Core Methylation Variants

MTHFR: Your Most Significant Methylation Finding

The MTHFR (methylenetetrahydrofolate reductase) gene encodes an enzyme that converts dietary folate into its most biologically active form, 5-methyltetrahydrofolate (5-MTHF). This active folate is essential for recycling homocysteine into methionine, which in turn feeds the production of SAMe (S-adenosylmethionine, the body's primary methyl donor molecule). Your results show two copies of the C677T variant, which research has consistently associated with reduced enzyme function.

MTHFR C677T

+/+

What this means: Carrying both copies of this variant is associated with substantially reduced MTHFR enzyme activity, which research indicates can lower the efficiency of converting folate into its active 5-MTHF form. This can influence homocysteine levels, particularly when dietary folate is limited.

Research context: Studies have linked C677T to differences in folate status and have observed that responses to dietary folate interventions can vary by genotype. The variant has also been studied in the context of pregnancy, cardiovascular markers, and folate-dependent processes.

Relevance to you: With frequent travel and skipped breakfasts, your folate intake may be inconsistent. Research suggests that individuals with this variant may benefit from the active methylfolate form rather than synthetic folic acid, and from prioritizing folate-rich whole foods such as leafy greens, legumes, and avocado. This may also be relevant to your afternoon brain fog, as folate and methylation support neurotransmitter production. Consider discussing folate form and dosing with your healthcare provider. Individual responses vary significantly.

MTHFR A1298C

-/-

What this means: You do not carry the A1298C variant. This is a favorable result. The A1298C variant, when present, has been studied in relation to BH4 (tetrahydrobiopterin) production, a cofactor important for neurotransmitter synthesis and ammonia processing.

Why it matters for you: Research indicates that the combination of C677T and A1298C variants (compound heterozygosity) tends to have a greater impact on folate metabolism than either alone. Because your A1298C is normal, the overall impact of your MTHFR profile may be somewhat less than if you carried both variants. This is an encouraging part of your results. As always, this is educational information only — consult your healthcare provider for personalized guidance.

Methylfolate (L-5-MTHF)

Form: L-5-Methyltetrahydrofolate (the active, pre-converted form of folate)

Typical research-informed dosage: 400–1000mcg daily, often taken in the morning with food

Why this form: Research suggests individuals with MTHFR C677T variants may process the active methylfolate form more readily than synthetic folic acid. Some individuals start at a lower dose (400mcg) and titrate upward as tolerated.

Important: Consult your healthcare provider before starting. Individual responses vary, and methylfolate can affect different people differently. This is educational information, not a prescription.

Methylcobalamin (Active B12)

Form: Methylcobalamin (the methylated, active form of vitamin B12)

Typical research-informed dosage: 500–1000mcg daily, often sublingual (under the tongue)

Why this pairs with methylfolate: Folate and B12 work together in the methylation cycle. Research indicates that combining active folate with active B12 may support more balanced homocysteine recycling, especially given your favorable MTR and MTRR core variants.

Important: Discuss with your healthcare provider, particularly if you have any history of B12-related conditions. Results are not guaranteed and vary by individual.

Connecting MTHFR to Your Brain Fog

Your afternoon brain fog could have many contributing factors, including your sedentary activity level, skipped breakfasts, and travel schedule. From a genetic standpoint, methylation supports the production of neurotransmitters (brain signaling chemicals) that influence focus and alertness. Studies indicate that adequate folate and B12 status supports these pathways. While this is not a diagnosis or treatment claim, optimizing methylation nutrition is one research-informed avenue worth exploring with your provider.



B₁₂ Recycling, Transsulfuration & Byproduct Processing

MTR & MTRR: Recycling Vitamin B₁₂

The MTR (methionine synthase) and MTRR (methionine synthase reductase) genes work as a team to recycle vitamin B₁₂ and to convert homocysteine back into methionine. Methionine synthase requires B₁₂ (specifically methylcobalamin) to function, and MTRR helps regenerate B₁₂ so it can be reused. Your core variants in this pathway are largely favorable.

MTR A2756G

-/-

What this means: You do not carry this variant, which is a favorable result. The A2756G variant, when present, has been studied in relation to B₁₂ utilization and homocysteine levels.

Why it matters for you: Research has observed that combinations of MTHFR C677T with MTR variants can be associated with more persistently elevated homocysteine. Because your MTR is normal, this particular compounding effect is less of a consideration in your profile — another encouraging finding that may partly balance your C677T status.

MTRR A66G

-/-

What this means: You do not carry the common A66G variant in MTRR, a favorable result. This variant has been studied in relation to B₁₂ recycling efficiency^[1].

Your secondary MTRR variants: You do carry single copies (+/-) of MTRR H595Y, K350A, and A664A. These are heterozygous findings, meaning one gene copy carries the variation and one does not. Research on these secondary MTRR variants is more limited than for A66G, and their individual impact is generally considered modest. Because your primary A66G is normal, your overall B₁₂ recycling capacity appears relatively well-supported. Consult your healthcare provider regarding B₁₂ status, particularly given your inconsistent multivitamin use.

CBS: The Transsulfuration Gateway

CBS A360A

+/-

What this means: You carry one copy of the CBS A360A variant. CBS (cystathionine beta-synthase) catalyzes the first step of the transsulfuration pathway, which directs homocysteine toward the production of cystathionine and ultimately compounds like cysteine, glutathione, and taurine.

Research context: CBS variants have been studied in relation to homocysteine levels, lipid markers, and sulfur metabolism. It is worth noting that much of the clinical commentary about CBS "upregulation" comes from clinical observation rather than large research studies, and findings in general populations have been mixed. Your favorable CBS C699T (-/-) and N212N (-/-) results suggest your transsulfuration pathway is not heavily affected. This single A360A copy is generally considered a modest finding. Discuss any sulfur-related dietary questions with your healthcare provider.

AHCY & BHMT: Byproduct Processing and Backup Routes

AHCY 01 / 02 / 19

+/+

What this means: You carry two copies each of three AHCY variants. AHCY (S-adenosylhomocysteine hydrolase) is the enzyme responsible for breaking down SAH (S-adenosylhomocysteine, the byproduct formed when SAMe donates a methyl group) into homocysteine and adenosine. Efficient SAH clearance is important because, as noted earlier, accumulating SAH can slow methylation reactions.

Research context: Genetic variation in the AHCY region has been studied in relation to one-carbon (methylation) metabolism and homocysteine handling. Some clinical commentators have suggested AHCY variations may modestly influence the balance of the methylation cycle. Given that your core MTR/MTRR pathway is favorable, supporting overall methylation nutrition (adequate folate, B12, and the cofactors discussed) is a reasonable research-informed approach. Adenosine, a product of this reaction, also plays a role in promoting sleep — a point of possible relevance to your slow sleep onset, though many factors contribute to sleep. Consult your healthcare provider.

BHMT-08

+/+

What this means: You carry two copies of the BHMT-08 variant. BHMT (betaine-homocysteine methyltransferase) provides an alternate "shortcut" route for converting homocysteine back to methionine, using betaine (trimethylglycine) as the methyl donor. This pathway is especially active in the liver and kidneys.

Research context: BHMT variants have been studied in relation to choline and betaine metabolism and homocysteine handling. Because your primary methylation route (via MTR/MTRR) is favorable, this backup pathway variation is generally considered a secondary finding. Research suggests that adequate dietary choline (found in eggs, fish, and your fish oil-adjacent food sources) supports the betaine pathway. Given that you skip breakfast often, you may be missing choline-rich morning foods like eggs — a point worth discussing with your healthcare provider as part of overall methylation support.

Betaine (Trimethylglycine / TMG)

Form: Trimethylglycine, also called betaine anhydrous

Typical research-informed dosage: 500–1000mg daily with food (some protocols use higher amounts under provider guidance)

Why it may be relevant: Betaine serves as the methyl donor for the BHMT backup pathway. Research suggests that adequate betaine and choline intake supports this route of homocysteine recycling. Dietary sources include beets, spinach, and whole grains.

Important: Consult your healthcare provider before supplementing, particularly to assess whether dietary choline and betaine intake may already be adequate. This is educational information only, not a prescription.

Your Methylation Profile: The Big Picture

Taken together, your methylation results show one significant variant (MTHFR C677T +/-) supported by largely favorable core recycling genes (normal MTR, MTRR A66G, and MTHFR A1298C). This is a relatively encouraging combination: your primary bottleneck appears to be at the MTHFR step, which research-informed nutritional strategies — centered on active methylfolate, active B12, and adequate dietary folate, choline, and betaine — may help support. Because you travel frequently and skip breakfast, consistency of nutrient intake may be as important as any single supplement. Please review these findings with your healthcare provider, who can consider testing (such as homocysteine or folate levels) and tailor any approach to your individual needs. This is educational information only, not medical advice, and individual responses vary significantly from research findings.

References

1. Association between maternal MTHFR and MTRR gene polymorphisms and the risk of congenital heart disease in newborns. BMC pediatrics. PMID: [41896807](#)



Detoxification Analysis

Your Detoxification Profile at a Glance

Watson, your genetic profile reveals a few notable patterns in how your body may process toxins, medications, and everyday compounds like caffeine. Research suggests your **CYP1A2** (a Phase 1 liver enzyme that breaks down caffeine) profile points toward relatively efficient caffeine metabolism, yet you also carry variants in antioxidant and conjugation pathways (**SOD2**, **GSTM1**, **GSTP1**, **NAT2**) that may influence how well your body neutralizes reactive byproducts.

This is educational information only, not medical advice. Individual responses vary significantly from research findings. Consider discussing these patterns with your healthcare provider, especially given your reported afternoon brain fog and heart palpitations after coffee.

Understanding Two-Phase Detoxification

Your body clears toxins, hormones, and medications through a coordinated two-step process in the liver. Understanding these phases helps explain why certain genetic variants may matter for how you feel day to day.

Phase 1 — Activation (CYP₄₅₀ Enzymes)

Phase 1 detoxification uses a family of enzymes called **cytochrome P450 (CYP450)** enzymes. These enzymes chemically modify toxins and drugs, often by adding oxygen, to make them more reactive. This step prepares compounds for the next phase. However, the intermediate products created here can sometimes be *more* reactive (and potentially more damaging) than the original substance until Phase 2 finishes the job.

Phase 2 — Neutralization (Conjugation)

Phase 2 detoxification attaches small molecules (such as glutathione, sulfate, or an acetyl group) to the reactive intermediates from Phase 1. This process, called **conjugation**, makes the compounds water-soluble so they can be safely eliminated in urine or bile. Key Phase 2 pathways include **glutathione conjugation** (GST enzymes), **sulfation** (SULT enzymes), **acetylation** (NAT enzymes), and **glucuronidation** (adding a sugar molecule to make toxins water-soluble, via UGT enzymes).

The balance between these two phases matters. When Phase 1 runs faster than Phase 2 can keep up, reactive intermediates may accumulate. Antioxidant defenses, including **SOD2** (Superoxide Dismutase 2, a mitochondrial enzyme that neutralizes harmful free radicals), help bridge this gap by clearing oxidative byproducts.

How Your Variants May Affect Toxin Processing

Gene	Your Genotype	Pathway	General Tendency
CYP1A2	AA (*1A/*1A)	Phase 1	Faster caffeine metabolism
CYP1A1	CT (+/-)	Phase 1	One altered copy
CYP1B1	GG (+/+)	Phase 1	Both copies altered
CYP2D6	CG / AG (+/-)	Phase 1	Intermediate metabolizer pattern
GSTM1	Present	Phase 2	Functional glutathione conjugation
GSTP1 I105V	AG (+/-)	Phase 2	Mildly reduced function
NAT2	Multiple +/-	Phase 2	Slow acetylator pattern
SOD2 A16V	AG (+/-)	Antioxidant	Intermediate enzyme activity

Environmental Exposure Considerations

Given your frequent work travel, skipped breakfasts, and moderate alcohol intake, your detoxification systems may face variable demands. Research suggests that individuals with slower Phase 2 conjugation patterns (such as your NAT2 slow acetylator profile) may benefit from steady support of antioxidant and glutathione pathways rather than relying on intermittent nutrition.

- **Cruciferous vegetables** (broccoli, kale, Brussels sprouts) provide compounds that research associates with supporting both Phase 1 and Phase 2 enzyme activity

- **Consistent protein intake** supplies amino acids (glycine, cysteine) used in conjugation reactions
- **Hydration** supports the elimination of water-soluble conjugated compounds
- **Limiting alcohol** may reduce competition for shared detoxification enzymes

A Note on Your Symptoms

Your reported afternoon brain fog, difficulty falling asleep, and palpitations after coffee may have multiple contributors. While genetics can offer clues, these symptoms warrant a conversation with your healthcare provider to rule out other causes. This report provides educational context, not a diagnosis.



Phase I Detoxification Genes

Phase I: Your CYP₄₅₀ Enzyme Profile

Your Phase 1 enzymes (the cytochrome P450, or CYP450, family) perform the first chemical step in processing caffeine, medications, hormones, and environmental compounds. The variants below may help explain your caffeine sensitivity and offer context for future medication conversations with your provider.

Why Phase I Matters for You

You mentioned heart palpitations after coffee and wondering whether genetics explain caffeine sensitivity. Phase 1 enzymes (especially CYP1A2) are central to this question. Let's explore what your variants suggest. Remember, individual responses vary, and this is educational information only.

CYP1A2

-/-

Your result (rs762551 AA): This genotype is associated with the more rapid caffeine metabolizer pattern. The CYP1A2 enzyme is responsible for breaking down roughly 95% of the caffeine you consume.

What research suggests: The AA genotype at rs762551 is generally linked to faster caffeine clearance compared to carriers of the C allele. Updated nomenclature and clinical impact reviews continue to characterize how CYP1A2 variation shapes individual responses to caffeine and other substrates^[1]. Studies on athletes have also examined how this variant interacts with caffeine pharmacokinetics and performance.

An apparent paradox: If you metabolize caffeine quickly, why the palpitations? Faster metabolism does not always mean fewer sensitivity symptoms. Rapid breakdown can produce metabolites quickly, and individual cardiovascular and nervous-system responses vary widely. Other genes affecting adrenaline-like compounds (such as COMT, covered separately) and your sleep patterns may also contribute. Research indicates dietary and metabolic gene profiles interact in complex ways.

Educational consideration: Research suggests that individuals noticing palpitations may benefit from observing their personal caffeine threshold and timing. Consuming coffee earlier in the day and tracking your response could provide useful information to share with your healthcare provider. Results are not guaranteed and may differ by individual.

CYP1A1

+/-

Your result (rs1048943 CT, CYP1A1*2C): You carry one altered copy of this Phase 1 enzyme, which participates in metabolizing aromatic compounds, certain environmental pollutants, and estrogen.

What research suggests: The CYP1A1*2C variant (rs1048943) has been studied extensively in relation to how the body processes environmental compounds and aromatic hydrocarbons^[2]. This locus has been associated with susceptibility patterns in various populations. Research also notes interactions between CYP1A1 activity and aryl hydrocarbon receptor signaling, which influences immune and metabolic responses.

Practical context: As a heterozygous carrier (+/-), you retain one fully functional copy. Research suggests that supporting this pathway with cruciferous vegetables (which contain compounds that modulate CYP1A1 activity) may be helpful. Given your frequent travel and variable diet, maintaining steady intake of these foods could offer supportive value. Consult your healthcare provider before making significant dietary changes.

CYP1B1

+/+

Your result (rs1056836 GG, L432V): Carrying two copies of this variant (+/+) is associated with altered CYP1B1 enzyme activity. This enzyme is involved in estrogen metabolism and the processing of certain environmental compounds.

What research suggests: The L432V variant (rs1056836) has been associated with differences in estradiol metabolism and has been studied in the context of metabolic traits including obesity^[3]. The variant has also been examined in relation to how the body handles specific compounds across different populations. Additional research has looked at this variant's role in survival and treatment-response contexts.

Practical context: When both gene copies carry this variation, research suggests the enzyme may metabolize estradiol somewhat differently. For a 45-year-old male, the day-to-day implications are modest, but supporting balanced hormone metabolism through cruciferous vegetables and maintaining a healthy body weight may offer supportive value. Discuss any hormone-related concerns with your healthcare provider.

CYP2D6

+/-

Your result (rs1135840 CG, rs1065852 AG): Your combination of variants suggests an intermediate metabolizer pattern for this important Phase 1 enzyme. CYP2D6 processes roughly 25% of commonly prescribed medications, including many antidepressants, beta-blockers, and pain medications.

What research suggests: Variants rs1065852 (CYP2D6*10) and rs1135840 (CYP2D6*41-associated) are well-characterized markers used to predict enzyme activity^[4]. Research on these variants informs how individuals may respond to medications metabolized by this pathway, including antidepressants^[5]. Next-generation sequencing studies have examined how accurately these variants predict actual enzyme function^[6].

Important note on medications: You currently take no medications, which is helpful context. However, should a healthcare provider consider prescribing antidepressants, beta-blockers, or certain pain medications in the future, sharing your CYP2D6 intermediate metabolizer status could inform their decision-making. This is educational information only. Never adjust or start any medication based on genetic data without provider guidance.

CYP3A4

-/-

Your result (rs2740574 TT, *1B not present): Your CYP3A4 profile reflects the typical-function pattern for this broadly important enzyme. CYP3A4 metabolizes an estimated 50% of all medications and many dietary compounds.

What research suggests: CYP3A4 variants influence the metabolism of a wide range of substrates, and studies use markers like rs2740574 to characterize enzyme activity^[7]. Recent candidate-gene research has used biomarkers to assess CYP3A-related activity in population cohorts^[8]. A systematic review has summarized prostate cancer susceptibility associations across CYP3A4 variants in European populations.

Practical context: Because your CYP3A4 appears typical-functioning, research suggests standard metabolism of most CYP3A4-processed compounds. One important interaction to remember: grapefruit juice inhibits CYP3A4. If you are ever prescribed a CYP3A4-metabolized medication, your provider may advise on grapefruit avoidance. This applies to everyone regardless of genotype.

Lifestyle Support for Phase 1 Balance

Research suggests several approaches may support balanced Phase 1 enzyme function:

- **Cruciferous vegetables:** Aim for several servings weekly to provide enzyme-modulating compounds
- **Caffeine timing:** Given your palpitations, consider limiting coffee to before noon and observing your response
- **Alcohol moderation:** Your 2–3 weekly drinks compete with detox enzymes; spacing them out may help
- **Consistent meals:** Skipping breakfast frequently may affect steady enzyme function; a protein-containing breakfast could provide supportive value

Consult your healthcare provider before making significant changes. Individual responses vary.

References

1. PharmVar GeneFocus: CYP1A2–Clinical Impact, Genetic Variation, and Updated Nomenclature. Clinical pharmacology and therapeutics. PMID: 41992662
2. The interaction between DNA methylation and single–nucleotide polymorphism in regulating the mRNA expression of CYP1A1, GSTP1 and GSTM1 in population. Toxicology letters. PMID: 41903599
3. The importance of CYP1B1 polymorphism in obesity. Medicine. PMID: 40355228
4. Establishment and Validation of Plasmid–based Reference Materials for CYP2D6*10 rs1065852 and *41 rs1135840 Detection Using Real–time PCR SNP Genotyping. Current pharmaceutical biotechnology. PMID: 42136290
5. [Personalized Pharmacotherapy with Sertraline in Patients with Anxiety–Depressive Disorder Based on Omics Biomarkers]. Molekuliarnaia biologii. PMID: 41477714
6. Does Next Generation Sequencing (NGS)–Based CYP2D6 Sequencing Improve Genotype–Phenotype Concordance in Tamoxifen–Treated Patients?. Clinical pharmacology and therapeutics. PMID: 42312965
7. Distribution of CYP3A4*1/*1B (rs2740574) and CYP3A5*1/*3 (rs776746) Genetic Variants in Renal Transplant Recipients Treated with Sirolimus in Urmia (Iran). Iranian journal of kidney diseases. PMID: 42234923
8. Candidate–gene–based study of CYP3A–related single–nucleotide polymorphisms using 4β–hydroxycholesterol/cholesterol ratio as biomarker in a Japanese cohort. European journal of clinical pharmacology. PMID: 42319470



Phase 2 Detoxification Genes

Phase 2: Conjugation and Antioxidant Defense

Phase 2 detoxification completes the work that Phase 1 begins by neutralizing reactive intermediates and preparing them for elimination. Your profile shows several variants in glutathione, acetylation, and antioxidant pathways that research suggests may benefit from targeted nutritional support.

Your Phase 2 Summary

Your **GSTM1** (a glutathione-related detox gene) appears present and functional, which is favorable. However, you carry a mildly reduced-function **GSTP1** variant, a **slow acetylator NAT2** pattern, and an intermediate-activity **SOD2** variant. Together, these suggest that consistent support of glutathione and antioxidant pathways may offer value. This is educational information; consult your healthcare provider before starting supplements.

GSTM1

-/-

Your result (rs366631 present, not deleted): Unlike many people who carry a complete deletion of this gene, your GSTM1 (Glutathione S-Transferase Mu 1) appears functional. This is a favorable finding for your detoxification capacity.

What research suggests: GSTM1 is part of the glutathione conjugation system, which attaches glutathione (the body's master antioxidant) to toxins to neutralize them. The GSTM1-null (deletion) genotype has been associated with reduced detoxification capacity and altered susceptibility patterns in numerous studies. Research has examined how GSTM1 status interacts with environmental factors and DNA methylation to regulate detox enzyme expression^[1]. Meta-analyses continue to evaluate GSTM1 polymorphisms in relation to environmental exposure outcomes^[2].

Practical context: Because you retain functional GSTM1, research suggests your glutathione-based detoxification has an advantage compared to deletion carriers. Supporting glutathione levels through adequate protein, sulfur-rich foods (garlic, onions, eggs), and cruciferous vegetables may help maintain this capacity. This is educational information only.

GSTP1 I105V

+/-

Your result (rs1695 AG, I105V): You carry one copy of the I105V variant, which research associates with mildly reduced GSTP1 enzyme function. GSTP1 (Glutathione S-Transferase Pi 1) helps conjugate glutathione to a range of toxins, including certain pollutants and reactive byproducts.

What research suggests: The I105V variant (rs1695) is one of the most studied GST polymorphisms and has been associated with altered enzyme activity and varied detoxification outcomes. Research has examined how GSTP1 variation interacts with chemotherapy efficacy and pharmacogenetic outcomes^[3]. Studies have also explored GSTP1's role alongside other genes in skin and tissue contexts^[4], and its association with respiratory conditions when both copies are affected.

Practical context: As a heterozygous carrier (+/-), you retain one fully functional copy. Research suggests that individuals with reduced GSTP1 function may benefit from supporting overall glutathione status. Approaches that research associates with glutathione support are discussed in the supplement section below. Consult your healthcare provider before starting any supplement.

NAT2

+/-

Your result (rs1801280 CT, rs1208 AG, rs1799929 not detected for several positions): Your NAT2 (N-Acetyltransferase 2) variant pattern is consistent with a slow acetylator phenotype. Acetylation is a Phase 2 process that attaches an acetyl group to compounds, including certain medications and aromatic amines found in cooked meats, cigarette smoke, and environmental sources.

What research suggests: NAT2 acetylator status is one of the best-characterized pharmacogenetic traits. Slow acetylators process certain drugs and environmental compounds more slowly. Research has associated NAT2 variability with glycemic control and metabolic outcomes^[5], and with how individuals respond to specific medications^[6]. The rs1801280 marker is widely used to infer slow acetylator status across populations.

Practical context: Research suggests that slow acetylators may benefit from moderating exposure to aromatic amines. Practical approaches include avoiding charred or heavily grilled meats, minimizing cigarette smoke exposure, and supporting overall Phase 2 capacity through balanced nutrition. Should you ever be prescribed medications metabolized by NAT2 (such as certain antibiotics), sharing your slow acetylator status with your provider may be valuable. This is educational information only, not medical advice.

SOD2 A16V

+/-

Your result (rs4880 AG, A16V): You carry one copy of this variant in SOD2 (Superoxide Dismutase 2), a critical mitochondrial enzyme that neutralizes superoxide free radicals, one of the most abundant reactive byproducts of energy production.

What research suggests: The A16V variant (rs4880) affects how efficiently SOD2 is transported into the mitochondria, influencing antioxidant capacity^[7]. Research has associated SOD2 rs4880 with oxidative stress markers and varied health outcomes including treatment-related toxicity^[8]. Studies have examined its role in oxidative stress biology across conditions^[9], and its association with radiotherapy-related oxidative outcomes^[10].

Practical context: As a heterozygous carrier (+/-), you have intermediate enzyme activity. Research suggests that supporting mitochondrial antioxidant defenses may offer value, particularly given your sedentary activity level and afternoon brain fog (which can have many causes, including oxidative and metabolic factors). Antioxidant-rich foods (colorful vegetables, berries) and the supplements discussed below may provide supportive value. Consult your healthcare provider for personalized guidance.

Supplement Considerations for Phase 2 Support

The following supplements are commonly discussed in research related to detoxification support. These are educational descriptions, not prescriptions. Consult your healthcare provider before starting any supplement, as individual needs and responses vary significantly.

NAC (N-Acetyl Cysteine)

Form: N-Acetyl-L-Cysteine

Typical dosage discussed in research: 600mg once or twice daily, often taken between meals

Rationale: NAC provides cysteine, a building block your body uses to produce glutathione (the master antioxidant central to your GSTM1 and GSTP1 pathways). Research suggests individuals with reduced glutathione-transferase function may benefit from supporting glutathione precursors. Consult your healthcare provider before starting.

Liposomal Glutathione

Form: Reduced glutathione (liposomal for improved absorption)

Typical dosage discussed in research: 250–500mg daily

Rationale: Given your GSTP1 +/- status and slow NAT2 acetylation, directly supplying glutathione is one approach research associates with antioxidant support. The liposomal form is designed to improve absorption. Individual responses vary; discuss with your healthcare provider.

Glycine

Form: Glycine powder or capsules

Typical dosage discussed in research: 3–5g daily, often taken in the evening

Rationale: Glycine is one of three amino acids your body combines to make glutathione, and it also participates in Phase 2 conjugation. As a bonus, glycine has been studied for its potential role in sleep quality, which may be relevant given your difficulty falling asleep. Consult your healthcare provider.

Milk Thistle (Silymarin)

Form: Standardized silymarin extract

Typical dosage discussed in research: 150–300mg silymarin daily

Rationale: Milk thistle is traditionally associated with liver support and antioxidant activity. Research has explored its role in supporting hepatic (liver) function. This is educational information only, not a treatment recommendation. Discuss with your healthcare provider.

Alpha Lipoic Acid

Form: R-Alpha Lipoic Acid (more bioavailable form)

Typical dosage discussed in research: 300–600mg daily, often with food

Rationale: Alpha lipoic acid is an antioxidant that research associates with supporting both water- and fat-soluble antioxidant systems and helping regenerate glutathione. Given your intermediate SOD2 antioxidant status, this may be of interest. Consult your healthcare provider before use.

DIM (Diindolylmethane) / Cruciferous Concentrate

Form: DIM or broccoli sprout extract

Typical dosage discussed in research: 100–200mg DIM daily

Rationale: DIM is a compound derived from cruciferous vegetables that research associates with supporting balanced Phase 1 and Phase 2 enzyme activity and hormone metabolism. Given your CYP1A1, CYP1B1, and GST variants, this aligns with cruciferous-vegetable support. If whole-food intake is inconsistent due to travel, a concentrate may offer supportive value. Discuss with your healthcare provider.

Important Supplement Reminder

These supplement descriptions are educational information only, not medical advice or prescriptions. Individual responses vary significantly from research findings, and results are not guaranteed. Always consult your healthcare provider before starting any supplement, especially if you develop new symptoms or begin any medication. Your provider can help determine what, if anything, is appropriate for your individual situation.

References

1. The interaction between DNA methylation and single-nucleotide polymorphism in regulating the mRNA expression of CYP1A1, GSTP1 and GSTM1 in population. *Toxicology letters*. PMID: 41903599
2. Glutathione S-Transferase Mu1 polymorphisms and environmental factors in cervical cancer susceptibility: a systematic review and meta-analysis. *Cellular and molecular biology (Noisy-le-Grand, France)*. PMID: 42322564
3. Impact of Pharmacogenetic Markers on the Efficacy of Neoadjuvant FLOT Chemotherapy in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma. *International journal of molecular sciences*. PMID: 42123691
4. Genetic analysis of genes GSTP1, PTEN, and TP53 SNPs in non-melanoma skin cancer patients. *Journal of cancer research and clinical oncology*. PMID: 42118341
5. Influence of NAT2 genetic variability on glycemic control in type 2 diabetes. *Clinica chimica acta; international journal of clinical chemistry*. PMID: 42229710
6. NAT2 rs1495741 and anti-tuberculosis drug-induced liver injury in children: genetic association and risk prediction. *Frontiers in pharmacology*. PMID: 42181880
7. The Dosage Effect of Manganese Superoxide Dismutase (MnSOD Val16Ala) Polymorphism in Acne Vulgaris and In Silico Identification Analysis of Biological Features of Variation. *Anais da Academia Brasileira de Ciencias*. PMID: 42018898
8. Ethnic Differences in the Association Between SOD2 rs4880 and Hepatotoxicity in Pediatric Acute Lymphoblastic Leukemia: A Report From the REDIAL Consortium. *Pediatric blood & cancer*. PMID: 42084208
9. Oxidative stress biomarkers across mood episodes in bipolar disorder: potential roles of TrxR1 and PRDX1. *BMC psychiatry*. PMID: 42151992
10. Genetic Polymorphisms in Genes Involved in Oxidative Stress and Their Association with Radiotherapy Toxicity among Head and Neck Cancer Patients. *Asian Pacific journal of cancer prevention : APJCP*. PMID: 41945939



Cardiovascular Health

Your Cardiovascular Genetic Profile

Your cardiovascular-related variants offer educational context around lipid metabolism, blood pressure regulation, clotting tendencies, and inflammation. Combined with your reported palpitations after coffee and sedentary lifestyle, these patterns may help inform conversations with your healthcare provider about heart-healthy habits.

Cardiovascular Summary

Your profile shows several variants associated with blood pressure regulation (**ACE**, **AGTR1**), cholesterol handling (**APOB**), clotting factors (**F2**, **F5** appear normal), and inflammation (**TNF**). Most findings suggest supporting cardiovascular wellness through standard heart-healthy approaches. This is educational information only. Consult your healthcare provider for personalized guidance.

ACE

+/-

Your result (rs4343 AG): You carry one copy of the ACE (Angiotensin-Converting Enzyme) insertion/deletion-associated variant. ACE plays a central role in regulating blood pressure and fluid balance through the renin-angiotensin system.

What research suggests: The rs4343 marker tags the ACE insertion/deletion polymorphism, which research has associated with blood pressure regulation and cardiovascular outcomes^[1]. Studies have examined the combined effect of ACE and angiotensinogen variants on hypertension risk^[2]. Research also notes that ACE variation may influence blood pressure response to dietary factors such as high-fat or high-salt intake.

Practical context: Research suggests that individuals carrying ACE variants may have blood pressure that is somewhat more responsive to dietary factors. Given your sedentary activity level and frequent travel eating, supporting cardiovascular health through regular movement, moderate sodium intake, and balanced meals may offer value. Periodic blood pressure monitoring with your healthcare provider is a reasonable consideration. This is educational information, not medical advice.

AGTR1

-/-

Your result (rs5186 AA): Your AGTR1 (Angiotensin II Receptor Type 1) genotype reflects the typical pattern at this position. This receptor mediates the blood-pressure-raising effects of angiotensin II.

What research suggests: The rs5186 variant (A1166C) in AGTR1 has been associated with hypertension risk and inflammatory markers in various populations. Research has examined how AGTR1 variation interacts with antihypertensive medication response^[3]. Machine-learning studies have also explored AGTR1-related pharmacogenomics in predicting cardiovascular outcomes^[4].

Practical context: Your typical-pattern result at this position is generally favorable for blood pressure regulation. Combined with your ACE finding, research suggests that standard heart-healthy habits, regular physical activity, balanced sodium, and stress management, may support cardiovascular wellness. Consult your healthcare provider about appropriate monitoring.

APOB

+/-

Your result (rs693 AG): You carry one copy of this APOB (Apolipoprotein B) variant. ApoB is the primary protein component of LDL (low-density lipoprotein) particles, often called "bad cholesterol," and is increasingly recognized as a marker of cardiovascular risk.

What research suggests: The rs693 variant has been associated with differences in LDL and total cholesterol levels. Research using Mendelian randomization approaches has examined ApoB's causal relationships with cardiovascular and metabolic outcomes. Studies have also explored ApoB in the context of lipid-related disease risk and lipid-lowering strategies.

Practical context: Research suggests that individuals carrying this variant may have a tendency toward modestly higher LDL and total cholesterol. Given your age (45), sedentary lifestyle, and travel-related dietary variability, this is useful context for cardiovascular conversations. Research associates omega-3 fatty acids, fiber-rich foods, and regular physical activity with supporting healthy lipid profiles. A standard lipid panel (including ApoB if your provider offers it) could provide actionable information. This is educational information only.

F2 (Prothrombin)

-/-

Your result (rs1799963 GG): Your prothrombin gene shows the typical, lower-risk pattern. The F2 gene encodes prothrombin, a key protein in the blood clotting cascade.

What research suggests: The rs1799963 variant (Prothrombin G20210A) is a well-established risk factor for venous blood clots when present. Your GG result indicates you do *not* carry this risk variant, which is a favorable finding. Research continues to characterize prothrombin-related clotting risk and its interactions with other factors. Studies have examined thrombophilia-related variants in relation to pregnancy and vascular outcomes^[5].

Practical context: Not carrying the prothrombin risk variant is reassuring for clotting-related cardiovascular health. Standard practices that support healthy circulation, staying hydrated, moving regularly (especially important given your frequent travel and sedentary lifestyle), and avoiding prolonged immobility during flights, remain valuable for everyone.

F5 (Factor V)

-/-

Your result (rs6025 CC): Your Factor V gene shows the typical pattern, meaning you do not carry the Factor V Leiden variant. Factor V is another key protein in the clotting cascade.

What research suggests: The rs6025 variant (Factor V Leiden) is the most common inherited clotting risk factor when present. Your CC result indicates you do not carry it, which is favorable. Research on Factor V Leiden continues to inform understanding of inherited clotting risk and its interactions with environmental factors such as hormonal exposures and immobility. Studies have also examined clotting-factor variants in the context of various vascular outcomes.

Practical context: Not carrying Factor V Leiden, combined with your normal prothrombin result, suggests a typical inherited clotting profile. This is reassuring. However, given your frequent work travel, general circulation-supporting habits, walking during long flights, staying hydrated, and avoiding prolonged sitting, remain wise for everyone regardless of genotype.

Your result (rs1800629 GG): Your TNF (Tumor Necrosis Factor) genotype reflects the typical, lower-inflammatory pattern at this position. TNF-alpha is a signaling molecule (cytokine) central to inflammation, which plays an important role in cardiovascular and metabolic health.

What research suggests: The rs1800629 variant (TNF-308) influences TNF-alpha production, and the A allele is associated with higher inflammatory output. Your GG result reflects the typical-production pattern. Research has examined TNF variants in relation to inflammatory and cardiovascular conditions, and in the context of depression and inflammation, which may relate to your reported brain fog.

Practical context: Your typical TNF pattern is generally favorable for managing inflammation. Research associates anti-inflammatory dietary patterns (rich in omega-3s, colorful vegetables, and whole foods) with supporting healthy inflammatory balance. Given your sedentary lifestyle, regular physical activity is also associated with anti-inflammatory benefits. This is educational information, not medical advice.

Cardiovascular Supplement Considerations

The following supplements are commonly discussed in cardiovascular research. These are educational descriptions only, not prescriptions. You already take fish oil and vitamin D, which is a reasonable foundation. Consult your healthcare provider before making changes.

Omega-3 EPA/DHA (Fish Oil)

Form: Concentrated EPA/DHA fish oil or algae-based omega-3

Typical dosage discussed in research: 2000-3000mg combined EPA/DHA daily, with meals

Rationale: You currently take 1000mg fish oil daily. Research associates higher omega-3 intake with supporting healthy triglyceride levels and cardiovascular wellness, which may be relevant given your APOB variant. Research suggests that individuals with FADS-related variants (affecting omega-3 conversion) may benefit more from direct EPA/DHA. Discuss optimal dosing with your healthcare provider, who can review your current intake.

CoQ10 (Ubiquinol)

Form: Ubiquinol (the reduced, more bioavailable form)

Typical dosage discussed in research: 100–200mg daily, with a fat-containing meal

Rationale: CoQ10 supports mitochondrial energy production and acts as an antioxidant, which may be of interest given your intermediate SOD2 antioxidant status and reported afternoon brain fog. Research associates CoQ10 with cardiovascular and cellular energy support. The ubiquinol form is often preferred for absorption in adults over 40. Consult your healthcare provider.

Magnesium Glycinate

Form: Magnesium glycinate (well-absorbed, gentle on digestion)

Typical dosage discussed in research: 200–400mg elemental magnesium daily, often in the evening

Rationale: Magnesium supports healthy blood pressure regulation, muscle and nerve function, and may relate to your reported sleep difficulty and palpitations (magnesium is involved in cardiac rhythm and relaxation). The glycinate form pairs magnesium with glycine, which may offer additional calming support. Many adults have suboptimal magnesium intake, especially with frequent travel eating. Consult your healthcare provider, particularly regarding palpitations.

Vitamin K2 (MK-7)

Form: Menaquinone-7 (MK-7)

Typical dosage discussed in research: 100–200mcg daily, with a fat-containing meal

Rationale: Vitamin K2 is associated with supporting healthy calcium metabolism, helping direct calcium toward bones rather than arteries. Research has explored K2's role in cardiovascular and bone health. It is often discussed alongside vitamin D (which you take seasonally) for complementary support. Consult your healthcare provider, especially if you ever take blood-thinning medications, as vitamin K interacts with them.

B-Vitamin Complex (Methylated Forms)

Form: B-complex with L-methylfolate and methylcobalamin

Typical dosage discussed in research: Varies by formulation; a balanced B-complex providing 400–800mcg L-methylfolate is commonly discussed

Rationale: Your MTHFR variants (covered in detail in Part 1 of your report) affect folate processing, which connects to homocysteine, an amino acid associated with cardiovascular health when elevated. Research suggests that individuals with MTHFR variants may benefit from methylated B-vitamin forms. Please refer to your Part 1 methylation analysis for detailed guidance, and discuss with your healthcare provider.

Diet and Lifestyle for Cardiovascular Wellness

Beyond supplements, research consistently associates several lifestyle approaches with supporting cardiovascular health. These may be particularly relevant given your sedentary activity level, frequent travel, and APOB variant.

- **Regular movement:** Research strongly associates even moderate physical activity with cardiovascular benefits. Given your sedentary status, gradually incorporating walking, especially after meals, may offer significant value
- **Heart-healthy eating pattern:** Mediterranean-style eating (rich in vegetables, olive oil, fish, nuts, and whole grains) is among the most researched dietary patterns for cardiovascular support
- **Consistent meals:** Frequently skipping breakfast may affect metabolic and energy patterns; a balanced morning meal could support steady energy and reduce afternoon brain fog
- **Caffeine awareness:** Given your palpitations, observing your personal caffeine tolerance and favoring earlier-day consumption may help
- **Alcohol moderation:** Your 2–3 weekly drinks are modest; keeping intake moderate supports both cardiovascular and detoxification health
- **Sleep prioritization:** Your difficulty falling asleep is worth addressing, as quality sleep is strongly associated with cardiovascular and cognitive health
- **Travel circulation:** During flights, walking periodically and staying hydrated supports healthy circulation

When to Consult Your Healthcare Provider

Your reported heart palpitations after coffee deserve direct attention from a healthcare provider. While they may relate to caffeine sensitivity, palpitations can have various causes, and a provider can perform appropriate evaluation. Additionally, given your APOB variant and sedentary lifestyle, a baseline cardiovascular assessment (including lipid panel and blood pressure) would provide valuable, actionable information. This genetic report offers educational context only; it does not diagnose, treat, or replace professional medical evaluation. Individual responses vary, and results are not guaranteed.

Bringing It Together

Watson, your cardiovascular and detoxification profile suggests a few practical themes: support your antioxidant and glutathione pathways (given your GSTP1, NAT2, and SOD2 variants), maintain heart-healthy habits (given your ACE and APOB variants), and pay attention to your caffeine response and sleep. Your favorable clotting (F2, F5) and inflammation (TNF) results are reassuring. The most impactful steps for someone with your profile, increasing physical activity, eating consistently, and addressing sleep, are accessible lifestyle changes. Partner with your healthcare provider to personalize this educational information into a plan that fits your individual situation.

References

1. Association of. Cardiovascular journal of Africa. PMID: 42347749
2. Combined AGT M235T-ACE I/D genotype and risk of essential hypertension in Vietnamese adults: a hospital-based case-control study. BMC cardiovascular disorders. PMID: 42310546
3. Associations between antihypertensive drug-related gene polymorphisms and cardiovascular outcomes in hypertensive patients: a gene-drug interaction study. Scientific reports. PMID: 41968188
4. Interpretable deep learning with pharmacogenomics predicts myocardial infarction in angiotensin receptor blocker treated hypertension. Journal of hypertension. PMID: 42052888
5. Genetic risk assessment of pregnancy-associated venous thromboembolism: dual utility of maternal peripheral blood in NIPT and VTE evaluation. BMC pregnancy and childbirth. PMID: 41491418



Mood & Neurotransmitter Analysis

Your Neurotransmitter Profile Summary

Hello Watson, this section explores how your genetic variations may influence mood, focus, stress response, and sleep. Based on your genetic data, several findings stand out that may relate to your reported symptoms of afternoon brain fog, difficulty falling asleep, and caffeine-related heart palpitations.

- **COMT V158M (rs4680): G/G genotype** — Associated with the faster-acting "warrior" variant of the COMT (Catechol-O-Methyltransferase, the enzyme that breaks down dopamine, norepinephrine, and estrogen) enzyme.
- **MTHFR C677T (rs1801133): A/A genotype** — Two copies of the reduced-function variant affecting folate processing, which connects to neurotransmitter production.
- **CYP1A2 (rs762551): A/A genotype** — Associated with faster caffeine metabolism, though other factors influence sensitivity.
- **VDR Taq (rs731236): A/A genotype** — A variant in the vitamin D receptor that research links to dopamine signaling.

This is educational information only, not medical advice. Individual responses vary significantly from research findings. Please consult your healthcare provider before making any changes.

How Neurotransmitters Shape Daily Function

Neurotransmitters are chemical messengers that allow brain cells to communicate. Three of the most important for mood and cognition are **dopamine** (drives motivation, focus, and reward), **serotonin** (supports mood stability and sleep), and **GABA** (gamma-aminobutyric acid, the brain's primary calming signal). The genes you inherited influence how quickly your body makes, uses, and breaks down these messengers.

Your reported afternoon brain fog and trouble falling asleep can have many contributing factors. From a genetic standpoint, the way you process dopamine (via COMT) and the efficiency of your methylation cycle (via MTHFR) are worth exploring, since both connect to neurotransmitter balance and energy.

Connection to Your Methylation Profile

As detailed in your methylation analysis, you carry two copies of the MTHFR C677T variant (rs1801133, A/A). Research indicates this variant reduces the MTHFR enzyme's folate-processing efficiency. Because methylation supports the production of neurotransmitters like dopamine and serotonin, this finding ties directly into your mood and cognition profile. Studies also link MTHFR variants to neurotransmitter-related processes. Discuss methylated B-vitamin options with your healthcare provider.

Key Neurotransmitter-Related Genes in Your Profile

Gene	Variant	Your Genotype	Primary Function
COMT V158M	rs4680	G/G	Dopamine/norepinephrine breakdown
COMT H62H	rs4633	C/C	Supports COMT enzyme activity
MTHFR C677T	rs1801133	A/A	Folate processing for neurotransmitter synthesis
MAOA R297R	rs6323	Not detected	Neurotransmitter breakdown
VDR Taq	rs731236	A/A	Vitamin D signaling, dopamine support
CYP1A2	rs762551	A/A	Caffeine metabolism

The following pages explore each of these systems in more detail. Remember that genetics provides only part of the picture — your sleep habits, diet, stress levels, and travel schedule all interact with these tendencies. This is educational information only. Results are not guaranteed and may differ by individual.



Dopamine Metabolism

Your Dopamine System

Dopamine is central to motivation, focus, reward, and the stress response. The most studied gene affecting dopamine is COMT (Catechol-O-Methyltransferase, the enzyme that breaks down dopamine, norepinephrine, and estrogen). The V158M variant (rs4680) is often described in terms of "warrior" versus "worrier" tendencies, reflecting differences in how quickly dopamine is cleared from the prefrontal cortex (the brain region governing planning, focus, and emotional regulation).

COMT V158M

-/-

Your result: G/G (often called Val/Val, or the "warrior" type).

What this means: Having two G alleles is associated with higher COMT (Catechol-O-Methyltransferase) enzyme activity, meaning dopamine and norepinephrine are broken down relatively quickly. Research on the Val158Met polymorphism indicates this faster-clearing variant influences pain modulation and stress processing. The variant has also been studied in relation to opioid and analgesic response^[1] and cognitive performance traits. Studies in dopaminergic pathways further connect this variant to behavioral outcomes^[2].

Practical relevance: Individuals with the warrior type often tolerate stress reasonably well but may sometimes experience lower baseline dopamine availability in the prefrontal cortex, which some people describe as reduced sustained focus — potentially relevant to your afternoon brain fog. Because this variant clears dopamine quickly, research suggests these individuals may respond well to supporting dopamine precursors. Consult your healthcare provider before starting any supplement.

COMT H62H

-/-

Your result: C/C at rs4633.

What this means: This variant is in close genetic linkage with V158M and helps define your overall COMT activity profile. The C/C result is consistent with the higher-activity COMT pattern seen with your V158M genotype. Research examining COMT polymorphisms in analgesic and pain-response contexts has included this marker as part of the COMT haplotype^[3]. Combined COMT haplotype analysis provides a more complete picture than any single variant alone.

Practical relevance: Together with your V158M result, this supports the interpretation that your COMT enzyme works relatively efficiently. This is educational information only and not a diagnosis.

MAOA and Dopamine Breakdown

MAOA (monoamine oxidase A) is another enzyme that breaks down dopamine, serotonin, and norepinephrine. Your file did not contain a reading for the common MAOA R297R variant (rs6323), so a full MAOA assessment is not possible from this data. Research links MAOA variation to mood and behavioral traits, and studies have examined its role in stress-related outcomes. If MAOA function is of interest, additional testing through your healthcare provider could provide clarity.

Research-Informed Support Options for Dopamine Balance

Because your warrior-type COMT clears dopamine quickly, research suggests individuals with this profile may benefit from gentle support of dopamine precursors and methylation. The following options are educational only — please discuss them with your healthcare provider, especially given your heart palpitations after coffee.

L-Tyrosine

Form: Free-form L-Tyrosine

Dosage: Research protocols often use 500–1000mg, typically taken in the morning on an empty stomach

Rationale: L-Tyrosine is a precursor the body uses to make dopamine. Individuals with fast-clearing COMT may find precursor support helpful for focus. Caution: tyrosine can be stimulating and may not be appropriate for those with palpitations or anxiety — consult your provider first.

SAMe (S-adenosylmethionine)

Form: Enteric-coated SAMe

Dosage: Research protocols commonly use 400–800mg daily, taken on an empty stomach

Rationale: SAMe (S-adenosylmethionine, the body's primary methyl donor molecule) supports methylation, which connects to your MTHFR variant. Studies indicate SAMe may support mood pathways. Start at a low dose; discuss timing and appropriateness with your healthcare provider.

Magnesium L-Threonate

Form: Magnesium L-Threonate (Magtein)

Dosage: 1000–2000mg daily, often taken in the evening

Rationale: Magnesium is a cofactor for many enzymes involved in neurotransmitter metabolism and may support brain health and relaxation. This form is studied for its ability to cross into brain tissue. May also support your reported sleep difficulties.

Rhodiola Rosea

Form: Standardized extract (3% rosavins, 1% salidroside)

Dosage: 200–400mg daily, taken in the morning

Rationale: Rhodiola is an adaptogenic herb traditionally used to support stress adaptation and mental energy. Some individuals report reduced afternoon fatigue. Individual responses vary significantly, and it may be stimulating for some — discuss with your provider.

Provider Consultation Reminder

Given your reported heart palpitations after coffee, please be cautious with stimulating supplements like L-Tyrosine and Rhodiola. These may amplify sensations of palpitations in some individuals. This is educational information only, not medical advice. Always consult your healthcare provider before starting any supplement, particularly if you experience cardiovascular symptoms.

References

1. Evaluating the Use of Tumor Bank DNA to Validate Genetic Factors Impacting Opioid Response in Patients with Advanced Cancer. *Current oncology (Toronto, Ont.)*. PMID: [42346263](#)
2. Dopaminergic system gene polymorphisms associated with severe obesity and related outcomes: A case-control study in Brazil. *Behavioural brain research*. PMID: [41999777](#)
3. Genetic Determinants of Analgesic Responsiveness: A Focus on CYP2D6 and COMT Polymorphisms in Chronic Pain. *The Clinical journal of pain*. PMID: [41521967](#)



Serotonin & GABA Systems

Serotonin & Calming Neurotransmitters

Serotonin supports mood stability, emotional resilience, and is a precursor to melatonin (the sleep hormone). GABA (gamma-aminobutyric acid) is the brain's main calming neurotransmitter, helping quiet mental activity for relaxation and sleep. Your reported difficulty falling asleep may relate to how these calming systems function in the evening.

Note on Your Serotonin Gene Coverage

Your genetic file focused primarily on methylation and detoxification panels. As a result, several classic serotonin-system markers (such as TPH2 variants, the 5-HTTLPR serotonin transporter, and HTR2A receptor variants) were not included in the data provided. The discussion below explains these systems generally and connects to the variants that were tested. For a deeper serotonin-system assessment, expanded testing through your provider may be helpful.

Serotonin Production (TPH2 System)

TPH2 (tryptophan hydroxylase 2) is the rate-limiting enzyme for serotonin production in the brain. Research links TPH2 variation to mood regulation, anxiety, and depression risk, and studies have examined its connections to suicide risk and behavioral traits. While your file did not include TPH2 markers, the methylation findings (MTHFR) are relevant here, since methylation indirectly supports serotonin synthesis.

Methylation Connection to Serotonin

MTHFR C677T

+/+

Your result: A/A (carrying both risk alleles).

What this means: Having two copies of this variant (+/+) is associated with substantially reduced MTHFR enzyme function, which lowers the body's production of active folate (5-MTHF). Research confirms this variant reduces folate-processing efficiency and affects folate status and methylation. Studies also examine its broader metabolic and oxidative-stress associations^[1].

Why it matters for mood: Active folate and methylation support the production of serotonin and dopamine. When both gene copies carry this variation, the methylation cycle may operate less efficiently, which is one reason individuals with this genotype sometimes explore methylated folate forms. Research has examined dietary and supplemental strategies to support folate status in carriers. Consult your healthcare provider before starting any folate supplementation.

GABA & Relaxation

The GABA system helps the brain shift into a calm, restful state — important for falling asleep. While your file did not include GAD1 or GABRA2 receptor markers, supporting GABA function through lifestyle and select nutrients is a common research-informed approach for individuals who report difficulty winding down at night, as you do.

Research-Informed Support Options for Mood & Calm

L-Theanine

Form: L-Theanine (Suntheanine)

Dosage: 200–400mg, often taken in the afternoon or evening

Rationale: L-Theanine is an amino acid from green tea studied for promoting calm focus without sedation. It may support relaxation pathways and is sometimes used to take the edge off caffeine-related jitteriness — potentially relevant given your palpitations after coffee. Individual responses vary.

Magnesium Glycinate

Form: Magnesium bisglycinate (chelated)

Dosage: 200–400mg of elemental magnesium, taken in the evening

Rationale: The glycinate form is well-absorbed and gentle on digestion. Magnesium supports GABA-related relaxation pathways and is widely studied for sleep quality and calm. Glycine itself (the attached amino acid) may also support sleep onset.

Omega-3 EPA

Form: EPA-dominant fish oil

Dosage: 1000–2000mg combined EPA, taken with food

Rationale: You already take 1000mg fish oil daily. Research suggests EPA-rich omega-3s may support mood and cognitive function. Lipidomic studies connect omega-3 pathways to mood-related processes^[2]. Note your FADS1 variant (discussed in your fatty acid analysis) may reduce conversion of plant omega-3s, making direct EPA/DHA more useful.

Taurine

Form: L-Taurine

Dosage: 500–1000mg, taken in the evening

Rationale: Taurine is an amino acid that may act on calming pathways and support relaxation. Some individuals find it helpful for evening wind-down. Consult your healthcare provider before adding it to your routine.

Important Note on 5-HTP and Mood Supplements

Supplements like 5-HTP and L-tryptophan are sometimes used to support serotonin, but they can interact with medications and are not appropriate for everyone. This is educational information only, not medical advice. Please consult your healthcare provider before considering any serotonin-affecting supplement, and remember that individual responses vary significantly from research findings.

References

1. Genetic variation of CBS (844ins68) and MTHFR A1298C among aluminum-exposed workers with emphasis on the role of oxidative stress. The Journal of the Egyptian Public Health Association. PMID: 42319700
2. Mendelian Randomization Identifies Lipidomic Signatures of Depression Risk That Are Partly Reflected in Cortisol-Induced Membrane Remodeling and Modulated by St. John's Wort Extract (Ze 117). International journal of molecular sciences. PMID: 42196323



Sleep & Circadian Rhythm

Your Sleep & Circadian Profile

Your circadian rhythm is your internal 24-hour clock that governs when you feel alert and when you feel sleepy. Genes including CLOCK, BMAL1, and the PER family (PER1, PER2, PER3) regulate this rhythm. You reported that it "takes forever to fall asleep," which makes this section especially relevant. Frequent work travel can also disrupt circadian timing, compounding any genetic tendencies.

Note on Circadian Gene Coverage

The genetic file provided centered on methylation and detoxification panels and did not include specific CLOCK, PER, or BMAL1 circadian markers. The guidance below therefore focuses on evidence-based sleep hygiene and nutrient support that research connects to sleep onset, along with the variants that were tested. Expanded circadian testing through your provider could add detail if sleep concerns persist.

Circadian Genes in Context

Research on circadian genes shows how variation can shift sleep timing and quality. PER3 variation, for example, has been studied in relation to circadian patterns and chronotype, and BMAL1 (also called ARNTL) variants have been examined for connections to metabolic and circadian regulation. The OPN4 melanopsin gene, which governs how your eyes signal light to your brain clock, has been linked to insomnia and seasonal mood patterns.

CYP1A2

-/-

Your result: A/A at rs762551 (often associated with the "fast metabolizer" pattern).

What this means: CYP1A2 is the primary liver enzyme that breaks down caffeine. The A/A genotype is generally associated with faster caffeine clearance. Research has examined how CYP1A2 variation affects caffeine pharmacokinetics and physical performance^[1], and updated reviews detail the clinical relevance of CYP1A2 genetic variation^[2]. CYP1A2 has also been studied in relation to caffeine and metabolic outcomes.

Practical relevance: Interestingly, you report caffeine sensitivity and palpitations despite carrying the fast-metabolizer genotype. This is a reminder that genetics is only one factor — palpitations after coffee can also relate to caffeine's direct effects on the heart, hydration, sleep deprivation, skipping breakfast, or individual sensitivity that genes do not fully explain. Even fast metabolizers may experience effects on sleep if coffee is consumed later in the day. Consider discussing your palpitations with your healthcare provider to rule out other causes.

Caffeine Timing & Your Symptoms

Given your difficulty falling asleep and afternoon brain fog, your 2–3 cups of coffee per day may be worth examining. Even with fast-metabolizer genetics, afternoon caffeine can interfere with sleep onset for some individuals. Research-informed sleep practices often suggest limiting caffeine to the morning. Skipping breakfast (which you mention) combined with coffee may also contribute to palpitations and energy dips. This is educational information only — please consult your healthcare provider about your caffeine intake and palpitations.

Evidence-Based Sleep Hygiene

- Aim to keep caffeine to before noon, especially given your trouble falling asleep.
- Get morning light exposure within an hour of waking to help anchor your circadian clock — particularly useful when traveling across time zones.
- Reduce bright and blue light in the 1–2 hours before bed, as light signals to your brain clock can delay sleep onset.
- Keep a consistent sleep and wake schedule when possible, even during work travel.

- Avoid eating large meals or alcohol close to bedtime; alcohol may fragment sleep even if it helps you feel drowsy initially.
- Consider a cool, dark, quiet sleep environment to support natural melatonin release.

Research-Informed Sleep Support Options

Magnesium L-Threonate or Glycinate

Form: Magnesium L-Threonate (for brain support) or Magnesium Glycinate (for relaxation)

Dosage: 200–400mg elemental magnesium, taken 30–60 minutes before bed

Rationale: Magnesium supports relaxation pathways and is one of the most studied minerals for sleep quality. The glycinate form pairs magnesium with glycine, which itself may support sleep onset.

Glycine

Form: Free-form glycine powder

Dosage: 3–5g taken before bed

Rationale: Glycine is an amino acid studied for supporting sleep onset and quality. Some individuals report falling asleep more easily and waking more refreshed. Given your reported difficulty falling asleep, this may be worth discussing with your provider.

Melatonin

Form: Standard or sustained-release melatonin

Dosage: Start low at 0.3–1mg, taken 30–60 minutes before bed; some protocols go up to 3mg

Rationale: Melatonin is the hormone that signals nighttime to your body. Lower doses are often as effective as higher ones for sleep onset. It may be especially useful for resetting your clock during work travel across time zones. Start with the lowest dose and consult your provider.

L-Theanine (Evening)

Form: L-Theanine

Dosage: 200mg in the evening

Rationale: L-Theanine promotes a calm mental state that may ease the transition to sleep. It pairs well with magnesium for evening wind-down. Individual responses vary.

Apigenin

Form: Apigenin (often derived from chamomile)

Dosage: 50mg before bed

Rationale: Apigenin is a flavonoid found in chamomile that is studied for its calming and sleep-supportive properties. It may complement other evening relaxation strategies.

Provider Consultation Reminder

Sleep supplements affect individuals differently, and persistent sleep difficulty deserves evaluation. This is educational information only, not medical advice. Please consult your healthcare provider before starting any sleep supplement, particularly given your reported heart palpitations. Results are not guaranteed and may differ by individual.

References

1. The Effect of CYP1A2 Gene Polymorphisms on Caffeine Pharmacokinetics and Exercise Performance in Male Recreational Athletes. European journal of sport science. PMID: [42230302](#)
2. PharmVar GeneFocus: CYP1A2–Clinical Impact, Genetic Variation, and Updated Nomenclature. Clinical pharmacology and therapeutics. PMID: [41992662](#)



Vitamin & Nutrient Metabolism

How Your Genes Influence Nutrient Processing

Your genes affect how efficiently you absorb, activate, and use key vitamins and minerals. Variations in receptors and conversion enzymes can mean some individuals benefit from specific nutrient forms or doses. This section reviews the nutrient-related variants found in your data, with particular focus on vitamin D (relevant since you note winter-only supplementation) and B12.

Vitamin D System

VDR Taq

+/+

Your result: A/A at rs731236 (VDR Taq).

What this means: VDR (the vitamin D receptor) determines how effectively cells respond to vitamin D. Having two copies of this variant (+/+) has been studied in relation to vitamin D-dependent processes. A systematic review and meta-analysis examined VDR polymorphisms including TaqI in relation to neurodegenerative outcomes. Other research has connected VDR variants to immune-metabolic mechanisms^[1] and to vitamin D status and related markers^[2].

Practical relevance: Vitamin D also supports enzymes involved in dopamine production, linking this finding to your mood and energy profile. Since you supplement vitamin D only in winter, research suggests individuals with VDR variants may benefit from monitoring vitamin D levels year-round and discussing consistent supplementation with their provider. Checking a 25-hydroxyvitamin D blood level is a practical first step.

VDR Bsm

-/-

Your result: C/C at rs1544410 (VDR Bsm).

What this means: The Bsm and Taq variants in VDR are often inversely related, and together they shape your overall vitamin D receptor profile. Your C/C result here represents the common genotype at this position. Research has examined the VDR BsmI variant in relation to vitamin D levels and various health outcomes^[3], and meta-analyses have evaluated BsmI alongside other VDR markers.

Practical relevance: This result, combined with your Taq A/A, suggests vitamin D status is worth monitoring. Adequate vitamin D supports mood, immune function, and bone health. Discuss appropriate testing and dosing with your healthcare provider.

B12 Absorption (FUT2 & Gut Health)

FUT2 is a gene that influences gut bacteria composition and B12 status, classifying individuals as "secretors" or "non-secretors." While your provided file did not include a FUT2 reading, this gene is worth noting because research connects FUT2 status to B12 levels and gut microbiome composition^[4], as well as to immune and infection-related traits^[5]. Given your MTHFR A/A status, optimizing B12 alongside folate is a common research-informed strategy, since the two work together in the methylation cycle.

Vitamin A Conversion (BCO1/BCMO1)

BCO1 (also called BCMO1) is the enzyme that converts beta-carotene from plant foods into active vitamin A. Variants can reduce this conversion efficiency, meaning some individuals get less active vitamin A from plant sources. Your detailed Genetic Lifehacks analysis flagged several BCO1 variants associated with decreased beta-carotene conversion. For individuals with reduced conversion, research-informed approaches sometimes include preformed vitamin A (retinol) sources alongside plant foods. Discuss any vitamin A supplementation carefully with your provider, as it is fat-soluble and can accumulate.

Summary of Nutrient-Related Genes

Gene	Variant	Your Status	Nutrient Relevance
VDR Taq	rs731236	A/A (+/+)	Vitamin D receptor response; monitor D levels
VDR Bsm	rs1544410	C/C (-/-)	Vitamin D receptor; common genotype
MTHFR C677T	rs1801133	A/A (+/+)	Active folate production; consider methylfolate

Gene	Variant	Your Status	Nutrient Relevance
BCO1/BCMO1	multiple	Reduced conversion variants	Beta-carotene to vitamin A conversion
MTRR A66G	rs1801394	A/A (-/-)	B12 recycling support
CYP2R1	rs10741657	Effect allele present	Vitamin D activation

Research-Informed Nutrient Support Options

Vitamin D₃

Form: Cholecalciferol (D3), preferably with a fat-containing meal

Dosage: Research protocols commonly use 2000–5000 IU daily, ideally guided by blood levels

Rationale: Given your VDR Taq variant and winter-only current use, research suggests individuals may benefit from year-round vitamin D support, adjusted to maintain healthy blood levels. Ask your provider to check a 25-hydroxyvitamin D level to personalize dosing. You currently take 2000 IU in winter; discuss whether continuing year-round makes sense.

Vitamin K₂ (MK-7)

Form: Menaquinone-7 (MK-7)

Dosage: 100–200mcg daily, taken with vitamin D3

Rationale: Vitamin K2 works synergistically with vitamin D to support proper calcium utilization and bone and cardiovascular health. Often paired with D3 supplementation. Note: if you ever take blood thinners, vitamin K requires provider guidance.

Methylcobalamin (B12)

Form: Methylcobalamin (active, methylated B12)

Dosage: 1000–5000mcg daily or several times weekly, often sublingual

Rationale: Given your MTHFR A/A status, the methylated form of B12 supports the methylation cycle alongside active folate. Research-informed protocols for MTHFR carriers often favor methylated B-vitamin forms. May support energy and mood. Consult your provider.

L-Methylfolate (5-MTHF)

Form: L-5-methyltetrahydrofolate (the active folate form)

Dosage: Research protocols vary widely; commonly 400–1000mcg daily — discuss the right level with your provider

Rationale: Because your MTHFR enzyme processes folic acid less efficiently, research suggests individuals with the A/A genotype may benefit from the pre-activated 5-MTHF form rather than synthetic folic acid. This connects directly to your methylation profile and supports neurotransmitter synthesis. Start conservatively and consult your provider, as some individuals are sensitive to methylfolate.

Quality Multivitamin (Methylated Forms)

Form: A high-quality, third-party tested multivitamin using methylated B-vitamin forms

Dosage: As directed on a reputable product, taken consistently with food

Rationale: You mention an inconsistent generic multivitamin. Given your MTHFR status, switching to a multivitamin containing methylfolate and methylcobalamin (rather than folic acid and cyanocobalamin) may better suit your genetics. Consistency matters more than potency — taking it regularly supports steady nutrient status.

Final Provider Consultation Reminder

The nutrient recommendations above are educational information only, not medical advice. Your individual needs depend on blood levels, diet, lifestyle, and overall health — factors best assessed by your healthcare provider. Individual responses vary significantly from research findings, and results are not guaranteed. Before starting any supplement, particularly given your reported heart palpitations and sleep concerns, please consult your healthcare provider for personalized guidance. Consider requesting blood tests for vitamin D, B12, and folate status to tailor any supplementation to your actual levels.

References

1. Genetic Polymorphisms of Vitamin D Receptor and Immune–Metabolic Mechanisms in Recurrent Pregnancy Loss: Narrative Review. *Biology*. PMID: [42274468](#)
2. Effect of vitamin D receptor gene Taql polymorphism on vitamin D levels and biochemical, inflammatory, and oxidative stress markers in individuals with obesity. *Molecular biology reports*. PMID: [42213218](#)
3. Association of The Vitamin D Receptor Gene BsmI and FokI Polymorphisms with Systemic Sclerosis Risk in a Tunisian Population. *La Tunisie medicale*. PMID: [42246707](#)
4. The HUNT study identifies host genetic factors reproducibly associated with human gut microbiota composition. *Nature genetics*. PMID: [41688637](#)
5. Ancestral FUT2 genetic adaptation confers resistance to modern norovirus and rotavirus infections. *Current opinion in virology*. PMID: [41764890](#)

Complete Supplement Protocol for Watson D. Crick

This educational protocol consolidates the supplement considerations identified throughout your genetic report (Parts 1–3) into a single actionable reference. The recommendations are organized by priority based on the impact of your specific genetic variants, including your **MTHFR C677T (+/+)** status, **CYP1A2 AA (slow-leaning caffeine metabolism context)**, **VDR Taq (+/+)**, and **BHMT–08 (+/+)** findings. This is educational information only, not medical advice. **Consult your healthcare provider before starting any supplement.** Individual responses vary significantly from research findings, and results are not guaranteed and may differ by individual.

Why These Recommendations May Be Relevant to You

Your profile combines a high-impact folate-processing variant (MTHFR C677T +/+, associated with reduced enzyme function) with reported symptoms of afternoon brain fog, difficulty falling asleep, and heart palpitations after coffee. Research suggests individuals with two copies of the MTHFR C677T variant may benefit from the active (methylated) form of folate rather than synthetic folic acid. Caffeine sensitivity is frequently studied in the context of CYP1A2 genetics^[1].

The table below lists all supplements discussed across your report. Studies indicate that the active folate form (L-5-MTHF) may support folate status in individuals carrying MTHFR variants, and a green-Mediterranean dietary pattern has been observed to interact with folate-metabolism genetics to influence serum folate. Forms and dosages are presented as ranges commonly used in research; your healthcare provider can help personalize these.

Supplement	Form	Dosage	Timing	Priority	Evidence / Rationale
Methylfolate	L-5-MTHF (active folate)	400–800mcg daily	Morning with food	Critical	Research suggests active folate may support folate status in MTHFR C677T (+/+) individuals
Methylcobalamin (B12)	Methylcobalamin	500–1000mcg daily	Morning with food	Critical	Works alongside folate in homocysteine recycling; studies of MTR/MTRR pathway variants note B12's role
Vitamin D3	Cholecalciferol	2000–4000 IU daily	Morning with fat-containing meal	Critical	Your VDR variants are studied in relation to vitamin D status and receptor binding; year-round use may be worth discussing given winter-only current intake

Supplement	Form	Dosage	Timing	Priority	Evidence / Rationale
Magnesium	Glycinate or L-Threonate	200–400mg elemental	Evening	Critical	Commonly studied for sleep and relaxation support; may be relevant to your reported sleep-onset difficulty
Omega-3 (EPA/DHA)	Triglyceride-form fish oil	1000–2000mg combined EPA/DHA	With a meal	High	FADS gene variants affect conversion of plant omega-3s, so direct EPA/DHA intake is often studied as more reliable
Riboflavin (B2)	Riboflavin / R5P	100–400mg daily	Morning with food	High	Research indicates riboflavin may support homocysteine metabolism in MTHFR C677T individuals, particularly where riboflavin status is low
Vitamin B6	P5P (pyridoxal-5-phosphate)	10–25mg daily	Morning with food	High	Cofactor in the transsulfuration pathway relevant to your CBS heterozygous status
Choline / Phosphatidylcholine	Phosphatidylcholine	300–500mg daily	With a meal	High	Your BHMT-O8 (+/+) and PEMT variants relate to choline–betaine pathways; choline supports an alternate methylation route
Trimethylglycine (Betaine/TMG)	Anhydrous betaine	500–1000mg daily	Morning	Medium	Supports the BHMT shortcut in homocysteine recycling; relevant given BHMT-O8 (+/+)
CoQ10	Ubiquinol	100–200mg daily	With a meal	Medium	General mitochondrial/cardiovascular support; discuss given reported palpitations
Zinc	Zinc glycinate	10–15mg daily	With food (not empty stomach)	Medium	Foundational mineral; SLC30A8 finding relates to glucose context
Vitamin C	Ascorbate	250–500mg daily	Morning	Medium	Antioxidant support; SLC23A1 transporter genetics influence plasma levels
Comprehensive Multivitamin (methylated)	Methylated B-complex base	1 serving daily	Morning with food	Medium	A consistent methylated multivitamin may replace your current inconsistent generic product

A Note on Your Current Supplements

You currently take fish oil (1000mg), seasonal vitamin D (2000 IU, winter only), and an inconsistent generic multivitamin. Research suggests your generic multivitamin could be replaced with a methylated version that provides L-5-MTHF rather than synthetic folic acid, which may be relevant given your MTHFR C677T (+/+) status. Year-round vitamin D may also be worth discussing with your provider. Consult your healthcare provider before making changes. This is educational information only, not medical advice.

References

1. The Effect of CYP1A2 Gene Polymorphisms on Caffeine Pharmacokinetics and Exercise Performance in Male Recreational Athletes. European journal of sport science. PMID: [42230302](#)



Phased Implementation Schedule

Start Low and Go Slow

Research-informed practice generally favors introducing supplements gradually rather than starting everything at once. This phased approach allows you to identify which supplement may be responsible if a reaction occurs and to assess tolerance individually. Individuals with MTHFR variants sometimes report sensitivity when first introducing methylated B-vitamins, so a low starting dose with gradual increases is often suggested. **Consult your healthcare provider before starting any supplement and before adjusting doses.**

The schedule below introduces Critical-priority supplements first, then layers in High and Medium priorities over subsequent weeks. Add only one new supplement every 2–3 days so that any individual reaction can be more easily identified. Keep a simple symptom and food journal, especially noting changes in your reported afternoon brain fog, sleep onset, and palpitations. Individual responses vary significantly from research findings.

Weeks 1-2: Foundation (Critical Priority)

- **Day 1–3:** Begin Methylfolate (L-5-MTHF) at the lower end of the range (400mcg) in the morning with food
- **Day 4–6:** Add Methylcobalamin (B12) 500mcg in the morning
- **Day 7–9:** Add Vitamin D3 2000 IU with a fat-containing meal
- **Day 10–12:** Add Magnesium (glycinate or L-threonate) in the evening, which may support your reported difficulty falling asleep
- **Day 13–14:** Hold steady and monitor tolerance before progressing

Weeks 3-4: Building (High Priority)

- Confirm your existing Omega-3 (fish oil) is consistent; consider adjusting toward 1000–2000mg combined EPA/DHA given FADS conversion genetics
- Add Riboflavin (B2) in the morning, which research indicates may support homocysteine metabolism in MTHFR C677T individuals

- Add Vitamin B6 (P5P) in the morning, a cofactor relevant to your CBS heterozygous status
- Add Choline / Phosphatidylcholine with a meal, relevant to your BHMT-O8 (+/+) finding

Week 5 and Beyond: Optimization (Medium Priority)

- Consider Trimethylglycine (TMG) to support the BHMT shortcut pathway
- Consider CoQ10 (ubiquinol) for general mitochondrial and cardiovascular support — discuss with your provider given reported palpitations
- Consider Zinc and Vitamin C as foundational support
- Transition your inconsistent generic multivitamin to a consistent methylated multivitamin
- Consider retesting relevant labs (e.g., homocysteine, vitamin D, B12) in 3–6 months to evaluate response

Monitoring for Side Effects

While introducing supplements, watch for changes in energy, mood, sleep, and any new symptoms. If you notice irritability, headaches, or sleep changes when starting methylated B-vitamins, research and clinical observation suggest lowering the dose or spacing it out may help — discuss with your healthcare provider. Because you report palpitations after coffee, also note whether reducing caffeine alongside this protocol changes how you feel. This is educational information only, not medical advice, and results are not guaranteed.



Drug Interactions & Safety Considerations

CRITICAL - Read Before Starting Any Supplements

Supplements can interact with prescription and over-the-counter medications. Although you report taking no medications currently, this section is provided for your future reference and to share with your healthcare provider. **Always inform your doctor and pharmacist about every supplement you take, especially before any surgery or if you begin a new medication.** This is educational information only, not medical advice. Never start, stop, or change a medication based on this report.

Your report identified several pharmacogenetic variants (including CYP1A2, CYP2C9, CYP2D6, CYP3A4, and VKORC1) that influence how the body processes various medications. Should you be prescribed medication in the future, these findings may be relevant to discuss with your prescriber. The interactions below are general, evidence-based considerations — each is presented because it is supported by published research.

Relevant Pharmacogenetic Context From Your Profile

- Variation in CYP1A2 is studied in relation to caffeine metabolism, which may be relevant to your reported caffeine sensitivity and post-coffee palpitations^[1]
- CYP2C9 and VKORC1 genetics are extensively studied in the context of warfarin dose requirements, relevant if anticoagulation is ever prescribed^[2]
- CYP2D6 variation influences metabolism of many antidepressants and other drugs
- CYP3A4 variation affects metabolism of numerous medications and is studied using biomarker ratios^[3]

General Supplement-Medication Interaction Considerations

Medication Class	Supplement of Concern	Consideration
Anticoagulants / antiplatelets (e.g., warfarin)	Omega-3 fish oil, Vitamin E	Vitamin K metabolism and warfarin dosing are influenced by VKORC1 and CYP4F2 genetics; discuss any high-dose omega-3 with your provider and pharmacist before combining with blood thinners

Medication Class	Supplement of Concern	Consideration
Antihypertensives (ARBs)	CoQ10, Magnesium	ARB response and cardiovascular outcomes are studied in relation to pharmacogenetics ^[4] ; monitor blood pressure if combining
Antidepressants (SSRIs/SNRIs metabolized by CYP2D6)	St. John's Wort, methylated B-vitamins	CYP2D6 activity scores affect antidepressant response and side effects; St. John's Wort can alter drug levels and should only be combined under provider supervision
Statins (HMGCR-targeting)	CoQ10	Statin pharmacology centers on HMGCR; CoQ10 is sometimes discussed alongside statins — review with your provider

Pregnancy, Breastfeeding & Special Situations

If you ever support a partner through pregnancy planning, note that folate-pathway genetics (including your MTHFR C677T +/- status) are studied in relation to pregnancy outcomes and folate needs. Supplement choices during pregnancy and breastfeeding should always be directed by a healthcare provider. Doses appropriate for a 45-year-old male may differ from those used in other life stages. This is educational information only, not medical advice.

Tell Your Healthcare Provider

Bring this report to your next appointment. Share your full supplement list, your reported symptoms (afternoon brain fog, slow sleep onset, post-coffee palpitations), and your pharmacogenetic findings. Your provider can determine whether any of these considerations apply to your individual situation. Individual responses vary, and results are not guaranteed.

References

1. The Effect of CYP1A2 Gene Polymorphisms on Caffeine Pharmacokinetics and Exercise Performance in Male Recreational Athletes. *European journal of sport science*. PMID: 42230302
2. SNP genotypes in CYP2C9 and VKORC1 genes do not affect prostate cancer or cancer mortality among warfarin users in Finnish prostate cancer patients. *PloS one*. PMID: 41056273
3. Candidate-gene-based study of CYP3A-related single-nucleotide polymorphisms using 4 β -hydroxycholesterol/cholesterol ratio as biomarker in a Japanese cohort. *European journal of clinical pharmacology*. PMID: 42319470
4. Interpretable deep learning with pharmacogenomics predicts myocardial infarction in angiotensin receptor blocker treated hypertension. *Journal of hypertension*. PMID: 42052888



Resources & Brand Recommendations

Supplement quality varies considerably between manufacturers. Because dietary supplements are not regulated as strictly as medications, choosing reputable, third-party-tested brands is one practical way to reduce the risk of contamination, mislabeling, or inaccurate dosing. The brand categories below are provided for educational purposes; inclusion does not represent an endorsement, and you should consult your healthcare provider before purchasing. Look for high-quality, USP-verified, or third-party-tested formulations rather than the cheapest available option.

Methylation Support (Active Folate & B-Vitamins)

- **Premium tier:** Thorne, Pure Encapsulations, Seeking Health, Designs for Health
- Look specifically for products listing **L-5-MTHF (methylfolate)** rather than folic acid, which research suggests may be more relevant for MTHFR C677T (+/+) individuals
- Choose **methylcobalamin** forms of B12 where possible

Magnesium (For Evening / Sleep Support)

- **Quality tier:** Doctor's Best (chelated/glycinate), NOW Foods (glycinate)
- **For cognitive context:** L-threonate formulations (e.g., Life Extension Neuro-Mag)
- Glycinate forms are often chosen for evening use due to tolerability

Omega-3 (Clean, Third-Party Tested)

- **Premium tier:** Nordic Naturals, Carlson Labs
- **Quality tier:** Sports Research, NOW Foods
- Direct EPA/DHA intake is often studied as more reliable than relying on conversion from plant sources, given FADS genetics

Vitamin D & General Wellness

- **Premium tier:** Thorne, Pure Encapsulations
- **Quality tier:** NOW Foods, Doctor's Best, Life Extension
- **Budget tier:** Nature Made, Kirkland (Costco) — many are USP-verified
- Vitamin D3 paired with a fat-containing meal supports absorption

Avoid Low-Quality Products With Unnecessary Fillers

Research suggests caution with very inexpensive supplements that may contain unnecessary fillers, artificial dyes, or inaccurate dosing. Because your current generic multivitamin is taken inconsistently and may contain folic acid rather than methylfolate, transitioning to a consistent, third-party-tested methylated product may be worth discussing with your provider. Consult your healthcare provider before starting any supplement.

Independent Supplement Quality Testing Resources

Third-party verification organizations can help you evaluate product quality and identify contamination or labeling issues:

- **ConsumerLab.com** — independent testing and reviews
- **Labdoor** — purity and label-accuracy rankings
- **USP Verified** — look for the USP mark on labels
- **NSF International** — certification for content and contaminant testing

These resources are provided for educational purposes only.

How to Retest and Monitor Progress

1. Establish a baseline by discussing relevant labs with your provider (e.g., homocysteine, vitamin D, B12, ferritin) before or shortly after starting
2. Keep a symptom journal tracking your afternoon brain fog, sleep onset time, and any palpitations
3. Reassess after approximately 3–6 months to evaluate whether the protocol is associated with any changes

4. Adjust only in collaboration with your healthcare provider — individual responses vary significantly from research findings

Final Reminder

This report provides educational information based on your genetic data and current research; it is not medical advice and is not intended to diagnose, treat, or cure any condition. Results are not guaranteed and may differ by individual. Always consult your healthcare provider before starting any supplement or making changes to your health routine.



Peptide Analysis

This section covers two distinct categories of peptide compounds: **GLP-1 agonists** (FDA-approved prescription medications such as semaglutide and tirzepatide) and **research peptides** (investigational compounds sometimes used in optimization and recovery contexts). These categories carry very different regulatory and safety considerations, and they are analyzed separately throughout this section.

Research suggests that genetics may influence how individuals respond to peptides. Receptor variants, metabolic pathway efficiency, and growth factor axis genes can all affect candidacy and the likelihood of response. This analysis examines the genetic variants present in your provided reports to offer educational context about peptide categories that may align with your profile. Individual responses vary significantly from population-level research findings.

How to Read This Section

Each peptide category is assigned a confidence tier based on how many relevant genetic variants were detected in your reports:

- **HIGH CONFIDENCE** — 3 or more relevant variants found with confirmed genotype results.
- **MODERATE CONFIDENCE** — 1 to 2 variants found; the full picture is incomplete.
- **INSUFFICIENT DATA** — No relevant variants found in this category. Only general educational context is provided, and no specific recommendation is made.

Recommendations in this section are generated only from genetic variants present in your provided reports. If a key gene was not found, no recommendation is made for that category — missing data is shown explicitly.

Cross-references to COMT and inflammatory variants analyzed earlier in this report are used without re-scoring those genes.

Important: Two Different Categories

GLP-1 agonists (semaglutide, tirzepatide) are FDA-approved prescription medications. Genetic candidacy analysis does not constitute a prescription. Always work with a prescribing physician.

Research peptides (BPC-157, Ipamorelin, and others) are investigational compounds not approved by the FDA for general human use. Always work with a knowledgeable provider experienced in peptide therapy.

This is educational information only, not medical advice.

What We Found in Your Genetic Data

What We Found in Your Genetic Data

The following table shows every peptide-relevant gene this analysis checked for, and whether it was detected in your provided genetic reports. This is the data foundation for all recommendations that follow.

Gene	SNP(s)	Category	Status in Your Data
GLP1R	rs10305492, rs6923761	GLP-1 response	Not detected
TCF7L2	rs7903146	GLP-1 response	Found: CT
FTO	rs9939609	Metabolic / GLP-1 context	Found: TT
MC4R	rs17782313	Appetite / GLP-1 context	Found: TT
GHSR	rs572169	GH axis	Found: CC
GHR	rs6873545	GH axis	Not detected
IGF1	rs35767	GH axis	Found: GG
IGF1R	rs2229765	GH axis	Found: AG
COL1A1	rs1800012	Tissue repair	Found: CC
VEGF	rs2010963	Tissue repair / angiogenesis	Found: GG
BDNF	rs6265 (Val66Met)	Cognitive peptides	Found: CT
COMT	V158M, H62H	Neurotransmitter (cross- ref)	See Part 3 — Mood & Neurotransmitter Analysis
Inflammatory (TNF, etc.)	Various	Inflammation (cross-ref)	See Part 2 — Detoxification & Cardiovascular

What 'Not detected' means

Your DNA testing provider may not report this particular variant, or it may not appear in the reports provided. This does not mean your gene is abnormal — it simply means this analysis cannot make a specific recommendation for this variant.



GLP-1 Agonist Response

GLP-1 Agonist Response (Semaglutide, Tirzepatide)

GLP-1 receptor agonists are medications that mimic the glucagon-like peptide-1 hormone, supporting glucose regulation and appetite control. This category includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Research suggests that receptor and metabolic pathway genetics may influence how strongly an individual responds to these medications. While the GLP1R receptor gene itself was not detected in your reports, several related metabolic variants were found that provide context for candidacy.

TCF7L2 rs7903146

CT

Impact: TCF7L2 is one of the most studied genes in type 2 diabetes risk, influencing beta-cell function and incretin signaling. The CT genotype carries one copy of the T risk allele, associated with altered insulin secretion. Studies indicate that TCF7L2 variants may modulate response to GLP-1-based therapies, with some research suggesting individuals carrying the T allele could show a somewhat different response profile. This variant supports relevance of GLP-1 pathway analysis for your profile.

FTO rs9939609

TT

Impact: FTO is the variant with the largest common genetic impact on BMI and appetite regulation. The TT genotype represents the non-risk (lower-BMI-associated) configuration. Research indicates that FTO genotype influences appetite and circadian-linked eating behavior, which is relevant context for appetite-modulating GLP-1 medications. Your lower-risk genotype suggests appetite-related metabolic risk may be less genetically driven in your case.

MC4R rs17782313

TT

Impact: MC4R is central to the melanocortin appetite-regulation pathway, the same system that GLP-1 signaling ultimately influences. The TT genotype here represents the non-C-risk configuration associated with typical appetite regulation. Research suggests MC4R pathway integrity is relevant to how appetite-modulating therapies are experienced.

GLP1R genotype not detected

The GLP1R receptor variants (rs10305492, rs6923761) were not detected in your reports. These variants directly affect the GLP-1 receptor itself and are the most specific predictors of GLP-1 medication response. Without this data, our GLP-1 assessment relies on related metabolic genes (TCF7L2, FTO, MC4R) and your general metabolic profile rather than direct receptor genotyping.

GLP-1 Candidacy Assessment

Based on 3 GLP-1-context metabolic variants analyzed (TCF7L2, FTO, MC4R), your profile suggests a **moderate candidate** picture. Your TCF7L2 CT genotype indicates relevance of the incretin pathway, while your FTO and MC4R genotypes suggest appetite regulation may be less genetically burdened. Because the direct GLP1R receptor variants were not detected, **Confidence: MODERATE**.

Prescription Required

GLP-1 agonists require a prescription. This genetic analysis identifies potential candidacy — it does not prescribe or recommend specific medications. Share this section with your prescribing physician or endocrinologist. Individual response varies significantly from population-level research findings.



GH Axis Peptides

GH Axis Peptides (Ipamorelin, CJC-1295, MK-677)

Growth hormone (GH) secretagogues are research compounds that stimulate the body's own GH and IGF-1 axis. Compounds in this category include Ipamorelin and CJC-1295 (which act on the GH-releasing pathways) and MK-677 (an oral ghrelin receptor agonist). These are typically explored in contexts of lean mass support, recovery, sleep quality, and body composition. Several GH axis genes were detected in your reports, providing meaningful context.

GHSR rs572169

CC

Impact: GHSR encodes the growth hormone secretagogue receptor — the very receptor that ghrelin-mimetic peptides like Ipamorelin and MK-677 target. The CC genotype represents the more common configuration. Research links GHSR variants to ghrelin signaling and appetite/GH regulation, making this gene directly relevant to GH secretagogue candidacy.

IGF1 rs35767

GG

Impact: IGF1 encodes insulin-like growth factor 1, the downstream mediator of growth hormone's anabolic effects. The GG genotype has been associated in research with insulin sensitivity and IGF-1 axis regulation. Because GH secretagogues ultimately work by raising IGF-1, this gene is central to predicting downstream response.

IGF1R rs2229765

AG

Impact: IGF1R encodes the IGF-1 receptor, which determines how tissues respond to the IGF-1 generated by GH stimulation. The AG heterozygous genotype carries one copy of the variant allele, which research has associated with differences in IGF-1 signaling and longevity-related phenotypes. This adds receptor-level context to the GH axis picture.

GHR genotype not detected

The GHR (growth hormone receptor) variant rs6873545 was not detected in your reports. This variant affects how directly tissues respond to growth hormone itself. Without this data, our GH axis assessment relies on the GHSR, IGF1, and IGF1R variants that were found.

GH Axis Candidacy Assessment

Based on 3 GH axis variants analyzed (GHSR, IGF1, IGF1R), your profile suggests a **moderate-to-strong candidate** picture for GH secretagogue compatibility, with receptor-level (GHSR, IGF1R) and downstream-mediator (IGF1) genes all represented. **Confidence: HIGH** (3 relevant variants found).

Investigational Compounds

Research peptides including Ipamorelin, CJC-1295, and MK-677 are investigational compounds not approved by the FDA for general human use. This genetic analysis suggests potential compatibility — it does not constitute a recommendation to obtain or use these compounds. Work with a physician experienced in peptide therapy. These compounds are not available at standard pharmacies and their purity and safety from unregulated sources cannot be guaranteed.



Tissue Repair Peptides

Tissue Repair Peptides (BPC-157, TB-500)

BPC-157 and TB-500 are research peptides explored in the context of connective tissue healing, gut lining integrity, angiogenesis (new blood vessel formation), and injury recovery. Their proposed mechanisms involve collagen organization and vascular signaling, so genes governing collagen structure and angiogenesis provide relevant genetic context. Both relevant tissue repair genes were detected in your reports.

COL1A1 rs1800012

CC

Impact: COL1A1 encodes the major component of type I collagen, the primary structural protein of tendons, ligaments, skin, and bone. The CC genotype is associated in research with typical collagen expression and, in some studies, reduced risk of certain tendon and ligament injuries. This is directly relevant to tissue repair peptide candidacy, since these compounds are explored for connective tissue support.

VEGF rs2010963

GG

Impact: VEGF (vascular endothelial growth factor) governs angiogenesis — a key mechanism proposed for tissue repair peptides like BPC-157. The GG genotype represents a common configuration associated with VEGF expression patterns. Because angiogenic capacity influences healing and recovery, this gene adds meaningful context to the tissue repair picture.

Inflammatory cross-reference

Inflammatory variant findings from your Detoxification & Cardiovascular Analysis (Part 2) are also relevant to tissue repair. Your **TNF -/- (normal)** status, analyzed in Part 2, suggests a baseline inflammatory profile that is not genetically amplified. In a tissue repair context, a non-elevated inflammatory tendency may support a more favorable healing environment, though individual responses vary significantly.

Tissue Repair Candidacy Assessment

Based on 2 tissue repair variants (COL1A1, VEGF) plus a favorable inflammatory cross-reference (TNF normal from Part 2), your profile suggests a **moderate-to-strong candidate** picture for tissue repair peptide compatibility. **Confidence: MODERATE** (2 direct variants plus 1 supportive cross-reference).

Investigational Compounds

Research peptides including BPC-157 and TB-500 are investigational compounds not approved by the FDA for general human use. This genetic analysis suggests potential compatibility — it does not constitute a recommendation to obtain or use these compounds. Work with a physician experienced in peptide therapy. These compounds are not available at standard pharmacies and their purity and safety from unregulated sources cannot be guaranteed.



Cognitive Peptides

Cognitive Peptides (Semax, Selank)

Semax and Selank are research peptides studied primarily in Eastern European clinical contexts for cognitive performance, stress resilience, and neuroprotection. One proposed mechanism is upregulation of BDNF (brain-derived neurotrophic factor), a protein central to learning, memory, and neuronal plasticity. Your BDNF genotype was detected, and your COMT status from Part 3 provides additional neurotransmitter context.

BDNF rs6265 (Val66Met)

CT

Impact: The BDNF Val66Met polymorphism influences activity-dependent BDNF secretion. The CT (Val/Met) genotype carries one copy of the Met allele, which research has associated with somewhat reduced BDNF release and differences in stress response and cognitive phenotypes. Because cognitive peptides such as Semax are proposed to modulate BDNF pathways, individuals with a Met allele may have particular interest in this mechanism — though studies indicate individual responses vary significantly.

COMT cross-reference

Your COMT variants (V158M and H62H), analyzed in Part 3 (Mood & Neurotransmitter Analysis), are also relevant to cognitive peptide candidacy. Your **COMT V158M -/- (normal)** and **COMT H62H -/- (normal)** status indicates faster, more typical breakdown of dopamine and other catecholamines. This affects the neurostimulatory threshold relevant for peptides that modulate dopaminergic and stress pathways. A normal-activity COMT profile suggests catecholamine clearance is not genetically slowed in your case.

Cognitive Peptide Candidacy Assessment

Based on your BDNF Val66Met (CT) genotype and your normal-activity COMT cross-reference from Part 3, your profile suggests a **moderate candidate** picture for cognitive peptide compatibility. The BDNF Met allele is the primary genetic point of interest here, balanced by a typical COMT clearance profile. **Confidence: MODERATE** (1 direct variant plus 1 supportive cross-reference).

Investigational Compounds

Semax and Selank are investigational peptides not approved by the FDA for general human use. They are most studied in Eastern European clinical research contexts. This genetic analysis suggests potential compatibility — it does not constitute a recommendation to obtain or use these compounds. Work with a physician experienced in peptide therapy who can advise on sourcing, dosing, and legal status in your jurisdiction.

Peptide Recommendation Summary

Peptide Recommendation Summary

The following table summarizes peptide candidacy based on your genetic profile. Rows marked 'Insufficient data' indicate that key variants for that category were not detected in your reports — these are included for transparency, not as a recommendation to investigate further without additional genetic data. This is educational information only, not medical advice. Individual responses vary significantly from population-level research findings.

Peptide	Category	Genetic Fit	Confidence	Key Genetic Basis	Notes
Semaglutide	GLP-1 agonist	Moderate candidate	Moderate	TCF7L2 CT; FTO TT; MC4R TT (GLP1R not detected)	Rx — discuss with prescribing physician
Tirzepatide	GLP-1 / GIP agonist	Moderate candidate	Moderate	TCF7L2 CT; FTO TT; MC4R TT (GLP1R not detected)	Rx — discuss with prescribing physician
Ipamorelin	GH secretagogue	Moderate-strong candidate	High	GHSR CC; IGF1 GG; IGF1R AG	Research compound — requires knowledgeable provider
CJC-1295	GHRH analog	Moderate-strong candidate	High	GHSR CC; IGF1 GG; IGF1R AG	Research compound — requires knowledgeable provider
MK-677	Oral ghrelin agonist	Moderate-strong candidate	High	GHSR CC; IGF1 GG; IGF1R AG	Research compound — requires knowledgeable provider
BPC-157	Tissue repair	Moderate-strong candidate	Moderate	COL1A1 CC; VEGF GG; TNF normal (Part 2)	Research compound — requires knowledgeable provider
TB-500	Tissue repair	Moderate-strong candidate	Moderate	COL1A1 CC; VEGF GG; TNF normal (Part 2)	Research compound — requires knowledgeable provider

Peptide	Category	Genetic Fit	Confidence	Key Genetic Basis	Notes
Semax	Cognitive	Moderate candidate	Moderate	BDNF Val66Met CT; COMT normal (Part 3)	Research compound — requires knowledgeable provider
Selank	Cognitive / anxiolytic	Moderate candidate	Moderate	BDNF Val66Met CT; COMT normal (Part 3)	Research compound — requires knowledgeable provider

Required Disclaimer — Please Read

This peptide analysis is provided for educational and informational purposes only. It does not constitute medical advice, a prescription, or a recommendation to obtain or use any compound.

GLP-1 agonists are FDA-approved prescription medications. Obtaining them requires a licensed prescriber.

All other peptides listed in this section are investigational research compounds not approved by the FDA for general human use. Their safety, purity, and legal status vary by jurisdiction.

Consult a qualified healthcare provider before making any decisions based on this analysis. Individual responses vary significantly from population-level research findings.

Results are not guaranteed and may differ by individual.



Disclaimers & Legal Information

⚠ IMPORTANT MEDICAL DISCLAIMER

This report provides educational information only and is NOT medical advice, diagnosis, or treatment.

NO MEDICAL CLAIMS

We make **no claims** that the information in this report will diagnose, treat, cure, or prevent any disease or health condition. Nothing in this report should be construed as medical advice or as a substitute for consultation with a qualified healthcare provider. This report does **not establish a doctor-patient or healthcare provider-patient relationship**.

FDA DISCLAIMER

These statements have not been evaluated by the Food and Drug Administration. The information provided is not intended to diagnose, treat, cure, or prevent any disease. The FDA has not approved genetic testing for determining nutritional supplement protocols.

EVIDENCE-BASED, NOT PRESCRIPTIVE

The supplement suggestions in this report are based on peer-reviewed scientific research linking genetic variants to nutrient metabolism and health outcomes. However, **nutrigenomics is a rapidly evolving field** and scientific understanding may change. We present information on what researchers have observed in studies, **not prescriptive medical recommendations** on what you should do.

AI-GENERATED CONTENT

This report was generated using artificial intelligence systems (Claude by Anthropic, Grok by xAI, or ChatGPT by OpenAI) to analyze and synthesize information. While all AI-generated recommendations have been reviewed by our team before delivery, **AI systems can make errors or produce inaccurate information**. We make no guarantees about the accuracy of AI-generated content.

NO GUARANTEES OR WARRANTIES

We make **no representations, warranties, or guarantees** about the accuracy, completeness, or usefulness of the information provided in this report. Individual responses to supplements can vary significantly from research findings. We **cannot guarantee any specific health outcomes**. Results may vary by individual.

INDIVIDUAL FACTORS

Your genetic variants are just **ONE factor** influencing your health and how you respond to nutrients. Diet, lifestyle, environment, stress, sleep, exercise, age, existing health conditions, medications, and many other factors all play critical roles in your health outcomes. This report cannot account for all variables affecting your health and wellbeing.

DRUG INTERACTION SCREENING LIMITATIONS

While we use AI to screen for potential interactions between the supplements suggested in this report and your reported medications, **AI systems can make errors and may not identify all potential issues**. This screening is not comprehensive and cannot account for all possible interactions. This screening should **not replace consultation with your healthcare provider or pharmacist**.

CONSULT YOUR HEALTHCARE PROVIDER

You **MUST** consult with a qualified, licensed healthcare provider before starting, stopping, or changing any supplement regimen. This is especially critical if you:

- Have existing health conditions (cardiovascular, kidney, liver, autoimmune, mental health, or any chronic conditions)
- Are pregnant, nursing, or planning to become pregnant
- Take prescription medications (especially blood thinners, antidepressants, blood pressure medications, or immunosuppressants)
- Have allergies or sensitivities to supplements or foods
- Are under 18 years old
- Have a history of adverse reactions to supplements

Your healthcare provider can review this report, order appropriate blood work, monitor your response, check for interactions with your specific medications, and make adjustments as needed for YOUR unique situation.

BLOOD WORK RECOMMENDED

We **strongly recommend** working with a healthcare provider to obtain baseline blood work (vitamins, minerals, inflammatory markers, etc.) before starting supplements, and follow-up testing to monitor your response. Some genetic variants may require higher or lower doses than suggested, which can only be determined through blood testing and clinical monitoring.

USE AT YOUR OWN RISK

By using this report, you acknowledge that you are doing so at your own risk. We are not liable for any adverse effects, health outcomes, complications, or consequences resulting from following or not following the information in this report. You assume **full responsibility and liability** for any decisions you make regarding your health, supplement use, or medical care.

SEEK IMMEDIATE MEDICAL ATTENTION

If you experience any adverse effects from supplements, or if you have or suspect you have a medical condition, **seek immediate medical attention** from a qualified healthcare provider. Discontinue any supplements causing adverse effects.

THIRD-PARTY PROCESSING ACKNOWLEDGMENT

Your genetic data was processed through third-party services (Genetic Genie and Genetic Lifehacks) to generate the genetic analysis portions of this report. While these services have strong privacy policies and delete your data according to their stated timelines, you acknowledge that your data was temporarily processed by these services. We do not control these third-party services.

SUPPLEMENT QUALITY DISCLAIMER

Any specific supplement products mentioned in this report are for **educational reference only** and are not endorsements. We receive no compensation for product recommendations. You are responsible for:

- Verifying the quality and purity of any supplements you choose to purchase
- Checking for third-party testing and certification (USP, NSF, ConsumerLab)
- Reading product labels for allergens and inactive ingredients
- Ensuring supplements are from reputable manufacturers
- Following dosing instructions on product labels

Privacy & Data Protection

Your genetic privacy is paramount to us:

- **Data deletion:** Your raw genetic data is automatically deleted from our systems within 48 hours of report generation
- **No sharing:** We never share your genetic information with insurance companies, employers, or third parties
- **Secure processing:** All genetic data analysis occurs on encrypted, secure servers
- **No stored profiles:** We do not maintain genetic profiles or databases of customer information
- **Full privacy policy:** Available at wholegene.health/privacy

Limitation of Liability

Whole Gene Health and its affiliates make no warranties, express or implied, regarding the accuracy, completeness, or usefulness of this information. We are not liable for any direct, indirect, incidental, or consequential damages arising from use of this report or the supplements recommended herein.

Scientific References

All recommendations are based on peer-reviewed scientific literature and established nutritional science. However, nutritional genomics is a rapidly evolving field, and recommendations may change as new research emerges.

Questions & Support

For questions about this report, please contact Whole Gene Health. For technical questions about Whole Gene Health services:

- **Email:** support@wholegene.health
- **Website:** wholegene.health
- **Response time:** We aim to respond to all inquiries within 24 hours

Report Information

Patient: Watson D. Crick

Report Generated: June 25, 2026

Report Version: 1.0

Data Source: Customer-provided genetic raw data

Thank you for choosing Whole Gene Health for your personalized genetic health insights. We're honored to be part of your wellness journey.